Chronic Vision Loss
Chronic vision loss is a gradual, progressive decline in visual acuity or visual field occurring over weeks to years, commonly caused by conditions such as cataracts, glaucoma, macular degeneration, or diabetic retinopathy.
Chronic Visual Loss
Chronic visual loss (also called gradual visual loss) refers to a progressive, insidious decline in visual acuity and/or visual field over weeks to months to years. This is in contrast to acute visual loss, which is sudden (seconds to days). The key conceptual distinction is that the patient often does not notice the loss until it is quite advanced, because:
- The fellow eye compensates.
- The brain "fills in" missing visual fields (particularly in glaucoma).
- The decline is so slow it becomes the patient's "new normal."
Chronic visual loss can be due to: (1) cloudy ocular media, e.g. corneal oedema, cataract, vitreous opacity; (2) retinal abnormalities, e.g. age-related macular degeneration, macular oedema, retinitis pigmentosa; (3) optic nerve pathologies, e.g. glaucoma, compressive optic neuropathy. [1][2]
This anatomical framework — media → retina → optic nerve — is the single most important organising principle for approaching chronic visual loss and is the framework used in the GC lectures.
2. Epidemiology and Burden
- Cataract is the leading cause of blindness worldwide (~33% of global blindness) and the most common cause of chronic visual loss overall.
- Glaucoma is the leading cause of irreversible blindness worldwide.
- Age-related macular degeneration (ARMD) is the leading cause of irreversible central vision loss in the developed world for those > 50 years.
- Diabetic retinopathy is the leading cause of blindness in working-age adults (20–65 years) globally.
- Hong Kong has an ageing population → cataract, ARMD, and glaucoma prevalence are all rising.
- Prevalence of glaucoma in Chinese ≈ 3–4% in those > 40 years. Importantly, normal-tension glaucoma (NTG) is more common in East Asians (including Chinese) than in Caucasians — up to 50–70% of primary open-angle glaucoma (POAG) in HK is NTG. This has huge implications because screening by IOP alone will miss most cases.
- Primary angle-closure glaucoma (PACG) is more common in Chinese and East/Southeast Asians due to shallower anterior chamber depth and shorter axial length (hypermetropic eyes). [1][3]
- Diabetic retinopathy: With ~10% prevalence of DM in HK, diabetic eye disease is a major public health burden. Diabetic macular oedema is the commonest cause of vision loss in DM patients. [4]
- High myopia is extremely prevalent in Hong Kong (prevalence of myopia ~80% in young adults, high myopia ~10–15%), contributing to pathological myopia, myopic macular degeneration, and increased risk of retinal detachment and open-angle glaucoma.
| Condition | Key Risk Factors |
|---|---|
| Cataract | Age (most important), UV exposure, DM, corticosteroid use, smoking, trauma, myotonic dystrophy |
| POAG / NTG | Age, family history, high myopia, thin central corneal thickness, ↑IOP (for POAG), East Asian ethnicity (for NTG), vascular dysregulation |
| PACG | Hyperopia, female sex, East/Southeast Asian ethnicity, shallow anterior chamber, increasing age, family history |
| ARMD | Age, smoking (strongest modifiable RF), Caucasian ethnicity (but increasing in Asians), family history, cardiovascular disease |
| Diabetic retinopathy | Duration of DM (80% have DR after 20 years), poor glycaemic control, HTN, smoking, pregnancy, rapid implementation of tight glycaemic control [4] |
| Compressive optic neuropathy | Pituitary macroadenoma, meningioma, craniopharyngioma, Graves' orbitopathy |
3. Anatomy and Function of the Visual Pathway
Understanding the anatomy is critical because the site of pathology determines the pattern of vision loss and the clinical approach.
Light travels through:
- Cornea → main refractive surface (contributes ~2/3 of total refractive power)
- Aqueous humour → fills anterior chamber, produced by ciliary body, drains via trabecular meshwork into Schlemm's canal (this is where glaucoma pathology occurs)
- Pupil → controls light entry
- Crystalline lens → fine-focuses (accommodates). This is where cataract develops.
- Vitreous humour → gel-like substance filling posterior segment
Any opacity in this pathway → ↓light reaching retina → ↓vision. The clinical clue is a diminished or absent red reflex.
- The retina is a neural tissue lining the posterior eye.
- Macula (specifically the fovea) is the area of highest cone photoreceptor density → responsible for central, high-acuity, colour vision.
- Peripheral retina has more rods → responsible for peripheral and dim-light (scotopic) vision.
- The retina has a dual blood supply:
- Inner retina → central retinal artery (branch of ophthalmic artery ← ICA)
- Outer retina (photoreceptors, RPE) → choroidal circulation (from posterior ciliary arteries)
- This dual supply is why in CRAO, the macula shows a "cherry red spot" — the thin fovea is still perfused by the choroid while the surrounding inner retina is ischaemic and whitened.
- Retinal pigment epithelium (RPE): a single-cell layer that supports photoreceptors, recycles visual pigments, and forms the outer blood-retinal barrier. Dysfunction of the RPE is central to ARMD pathogenesis.
- Retinal ganglion cell axons converge at the optic disc → exit as the optic nerve (CN II).
- The optic nerve passes through the optic canal and the two optic nerves meet at the optic chiasm (where nasal fibres decussate).
- Post-chiasm: optic tracts → lateral geniculate nucleus (LGN) → optic radiations → primary visual cortex (V1, Brodmann area 17) in the occipital lobe.
Pattern of visual field loss by lesion site:
| Lesion Site | Visual Field Defect | Classic Cause |
|---|---|---|
| Optic nerve (pre-chiasmal) | Ipsilateral monocular vision loss (central scotoma, altitudinal defect, or diffuse) | Glaucoma, optic neuritis, compressive lesion |
| Optic chiasm | Bitemporal hemianopia | Pituitary tumour [5] |
| Optic tract | Contralateral homonymous hemianopia | Stroke, tumour |
| Temporal optic radiation (Meyer's loop) | Contralateral homonymous superior quadrantanopia ("pie in the sky") | Temporal lobe lesion |
| Parietal optic radiation | Contralateral homonymous inferior quadrantanopia ("pie on the floor") | Parietal lobe lesion |
| Occipital cortex | Contralateral homonymous hemianopia with macular sparing | PCA stroke |
Aqueous humour is produced by the ciliary body → flows from the posterior chamber through the pupil into the anterior chamber → drains through the trabecular meshwork (90%, conventional outflow) and the uveoscleral pathway (10%) into Schlemm's canal → episcleral veins.
- Normal IOP = 10–21 mmHg.
- When outflow is impeded (e.g. trabecular meshwork dysfunction in POAG, or pupillary block in PACG), IOP rises.
- Elevated IOP causes mechanical and vascular damage to retinal ganglion cell axons at the lamina cribrosa of the optic disc → progressive optic neuropathy = glaucoma.
- In normal-tension glaucoma, the IOP is within the "normal" range but the optic nerve is still damaged — likely due to vascular insufficiency or increased susceptibility of the optic nerve head.
4. Aetiology (with Focus on Hong Kong) and Pathophysiology
The aetiologies are best organised by the anatomical framework:
4.1 Cloudy Ocular Media
Definition: Clouding or loss of clarity of the crystalline lens.
Cataract refers to clouding or loss of clarity of crystalline lens. May be congenital, senile, traumatic, drug-related or secondary to ocular disease. Presents with painless loss of vision with glare and often myopic shift. Can be associated with leukocoria (whitish appearance of pupils). Clinically with ↓red reflex with black opacification that obscures underlying retina but not the iris. [1][2]
Aetiology/Classification by cause:
| Type | Mechanism |
|---|---|
| Senile/age-related (most common) | Cumulative oxidative damage to lens proteins (crystallins) → protein aggregation → opacification |
| Diabetic | Hyperglycaemia → aldose reductase converts glucose to sorbitol (polyol pathway) → ↑accumulation of sorbitol within the lens [4] → osmotic swelling → lens fibre disruption → cataract |
| Corticosteroid-induced | Posterior subcapsular cataract; mechanism involves glucocorticoid receptor-mediated changes in lens epithelial cells |
| Traumatic | Blunt/penetrating injury → disruption of lens capsule/fibres |
| Congenital/infantile | TORCH infections, metabolic (galactosaemia), genetic |
| Secondary to ocular disease | Chronic uveitis, prior vitrectomy, retinal detachment surgery |
| Others | Radiation, myotonic dystrophy ("Christmas tree" cataract), Wilson's disease (sunflower cataract) |
Morphological classification (senile cataract):
- Nuclear sclerotic: central lens nucleus hardens and yellows → myopic shift (because the refractive index of the dense nucleus increases, bending light more → the "second sight of the aged" where presbyopic patients temporarily can read without glasses). This is why the AOS scenario states "the optician noted the patient was more short-sighted than at a previous examination 1 year ago" — classic nuclear sclerotic cataract. [3]
- Cortical: spoke-like (wedge-shaped) opacities in the lens cortex; significant glare.
- Posterior subcapsular: opacity at the back surface of the lens, just in front of the posterior capsule; worst for near vision and in bright light; associated with steroids and DM.
Pathophysiology in detail:
- The lens is avascular (receives nutrients from aqueous humour) and relies on antioxidant defences (glutathione, ascorbate) to prevent oxidative damage to crystallin proteins.
- With ageing, cumulative UV exposure and oxidative stress → crystallin protein denaturation and aggregation → light scattering → opacification.
- In DM: the polyol pathway (aldose reductase pathway) is particularly relevant. Excess glucose → converted to sorbitol by aldose reductase → sorbitol does not cross cell membranes → osmotic stress → lens fibre swelling and disruption → early cataract.
Causes include corneal oedema resulting from chronic corneal irritation or defective endothelial function (e.g. chronic anterior uveitis, previous trauma, cataract surgery), interstitial keratitis due to syphilis/TB, band keratopathy, corneal scarring. Diagnosed by reduced red reflex with black opacification that obscures details of the underlying iris. [1]
- Key distinction from cataract: corneal opacity obscures the iris detail on slit-lamp examination, whereas cataract obscures the retinal detail (retina is behind the lens) but you can still see the iris.
- In HK: trachoma (Chlamydia trachomatis) was historically a major cause of corneal scarring but is now rare. Current common causes include Fuchs' endothelial dystrophy, bullous keratopathy post-cataract surgery, herpetic keratitis scarring.
- Chronic vitreous haemorrhage (e.g. from proliferative diabetic retinopathy) or asteroid hyalosis can cause gradual visual degradation.
4.2 Retinal Disorders
Pathophysiology: Retinal microangiopathy — chronic hyperglycaemia → metabolic changes in retinal vessels → impaired vascular autoregulation → microaneurysm + retinal haemorrhage ('dot-and-blot'). Retinal ischaemia: endothelial damage → microthrombosis or occlusion → ischaemia → cotton wool spots (retinal nerve infarct) + venous beading (due to ischaemia) + intra-retinal microvascular abnormalities (IRMA) (anastomosis between arterioles and venules). Breakdown of blood-retinal barrier: microangiopathy + microthrombosis → ↑capillary leakage → hard exudates (lipoprotein leakage) + macular oedema (if occurring near macula) + retinal oedema. Vasoproliferative substances: ischaemia → vasoproliferative factor secretion (e.g. VEGF) → neovascularization (PDMR) + exacerbates ischaemia + breakdown of B-R barrier. Proliferative DMR: neovascularization with fragile vessels → vitreous haemorrhage. [4]
Classification (ETDRS-based, simplified):
| Stage | Key Findings | Pathophysiology |
|---|---|---|
| Mild NPDR | Microaneurysms only | Earliest sign; focal outpouchings of weakened capillary walls |
| Moderate NPDR | Microaneurysms + dot-blot haemorrhages + hard exudates ± cotton wool spots | Increasing vascular leakage and early ischaemia |
| Severe NPDR ("4-2-1 rule") | Any ONE of: haemorrhages in all 4 quadrants, venous beading in ≥ 2 quadrants, IRMA in ≥ 1 quadrant | Significant ischaemia driving VEGF production; high risk of progression to PDR |
| Proliferative DR (PDR) | Neovascularization of disc (NVD) or elsewhere (NVE), ± vitreous/pre-retinal haemorrhage, ± tractional retinal detachment | New fragile vessels grow in response to VEGF; can bleed into vitreous or contract and pull retina off |
Diabetic macular oedema (DMO) can occur at any stage of DR and is the commonest cause of vision loss in DM patients [4]. It results from breakdown of the inner blood-retinal barrier → fluid accumulation in the macula → ↓central VA.
In the vast majority, DR has no symptoms until the very late stages where there is gradual or sudden deterioration in visual acuity. [1]
This is why screening is so critical.
Definition: Degenerative disease of the macula in individuals > 50 years, characterised by progressive loss of central vision.
Two forms:
- Dry (atrophic/non-exudative) ARMD (85–90%): Slow, progressive. Drusen (extracellular deposits between RPE and Bruch's membrane) → RPE atrophy → geographic atrophy → gradual central vision loss.
- Wet (neovascular/exudative) ARMD (10–15%): Rapid. Choroidal neovascularization (CNV) grows through defects in Bruch's membrane → subretinal fluid/haemorrhage → rapid central vision loss. Although less common, wet ARMD accounts for 90% of severe vision loss from ARMD.
Pathophysiology:
- Drusen are the hallmark: accumulations of lipids, proteins, and complement components between the RPE and Bruch's membrane. They represent failure of the RPE to clear metabolic waste.
- Bruch's membrane thickens and calcifies with age → impairs nutrient diffusion from choroid to RPE → RPE dysfunction and death → photoreceptor loss (geographic atrophy).
- In wet ARMD: ischaemia and inflammation trigger VEGF secretion → choroidal neovascularization.
- Complement pathway dysregulation (polymorphisms in complement factor H, factor B) plays a major genetic role.
Symptoms:
- Gradual central blurring (dry) or sudden central distortion/metamorphopsia (wet) — patients notice straight lines appear wavy (e.g. door frames, venetian blinds).
- Tested with Amsler grid: patient fixates on central dot; wavy/missing lines suggest macular pathology.
Definition: A group of inherited retinal dystrophies characterised by progressive degeneration of photoreceptors, primarily rods.
- "retinitis" = retinal inflammation (though actually degenerative, not inflammatory — historical misnomer), "pigmentosa" = pigment deposits.
- Pathophysiology: Genetic mutations (many genes; can be AD, AR, or X-linked) → rod photoreceptor apoptosis → secondary cone degeneration.
- Symptoms: Night blindness (nyctalopia) first (because rods die first) → progressive tunnel vision (peripheral VF constriction) → eventually central vision loss.
- Signs: Classic triad on fundoscopy: (1) bone-spicule pigmentation in mid-periphery, (2) arteriolar attenuation, (3) waxy pallor of optic disc.
- HK relevance: relatively uncommon (~1:4000) but important cause of blindness in young adults; associated syndromes include Usher syndrome (RP + sensorineural deafness) and Bardet-Biedl syndrome.
Given the extremely high prevalence of myopia in Hong Kong, this is a locally important cause.
- High myopia (axial length > 26 mm or > −6D) → progressive elongation of the globe → mechanical stretching of the retina, RPE, and choroid → lacquer cracks (breaks in Bruch's membrane) → choroidal neovascularization or macular atrophy.
4.3 Optic Nerve Pathologies
Definition: A group of optic neuropathies characterised by progressive retinal ganglion cell loss with corresponding optic disc cupping and visual field defects. IOP is the most important modifiable risk factor, but glaucoma is NOT defined by IOP alone.
The name "glaucoma" comes from Greek glaukos = blue-grey/green (the colour the pupil can appear in advanced cases with corneal oedema).
Classification:
Pathophysiology of POAG:
- Trabecular meshwork dysfunction → ↑resistance to aqueous outflow → ↑IOP → mechanical compression and ischaemia at the lamina cribrosa (the sieve-like structure where RGC axons exit the eye) → axonal transport disruption → retinal ganglion cell apoptosis → optic disc cupping → VF loss.
- The pattern of damage is characteristic: arcuate nerve fibre bundle defects → nasal step → eventually complete VF loss. The reason for this pattern is that the arcuate fibres (from the temporal retina, arching over and under the macula) are most vulnerable at the superior and inferior poles of the optic disc.
- Central vision is spared until late (because the papillomacular bundle, serving the macula, is relatively resistant) → patients present late.
Normal-tension glaucoma:
- Same optic disc cupping and VF loss but IOP is consistently ≤ 21 mmHg.
- Pathophysiology likely involves vascular insufficiency (impaired perfusion of the optic nerve head), possible vasospasm (association with migraine, Raynaud's phenomenon), and/or increased susceptibility of the ganglion cells to normal IOP levels.
- Very relevant in Hong Kong — the majority of POAG in Chinese populations is NTG.
Primary angle-closure glaucoma (PACG):
- Anatomical predisposition: short axial length (hyperopic eye), shallow anterior chamber, thick/anteriorly positioned lens, plateau iris.
- Pupillary block is the most common mechanism: the iris bows forward against the lens → blocks aqueous flow from posterior to anterior chamber → aqueous accumulates behind the iris → iris bows further forward → mechanically closes the drainage angle → ↑IOP.
- Chronic angle closure → gradual synechial closure of the angle → progressive IOP elevation → chronic visual loss (this is distinct from the dramatic acute angle-closure crisis).
In rubeosis iridis, abnormal angiogenesis causes growth of blood vessels into angle of eye. Ensuing fibrosis results in acute angle closure and thus glaucoma. [4] — This is a form of secondary neovascular glaucoma, commonly seen as a complication of proliferative diabetic retinopathy or CRVO.
- Pituitary adenoma: The classic compressive lesion. The optic chiasm sits just above the pituitary gland → a suprasellar extension of a pituitary macroadenoma compresses the chiasm → bitemporal hemianopia [5]. Slow-growing → gradual, painless visual field loss, often noticed as bumping into things or difficulty driving.
- Meningioma (e.g. sphenoid wing, olfactory groove, tuberculum sellae): can compress the optic nerve or chiasm.
- Craniopharyngioma: suprasellar tumour, often in children/adolescents; calcification is classic on imaging.
- Graves' orbitopathy: Oversized recti + orbital fat → apical crowding → compressive optic neuropathy → slowly progressive ↓vision (esp colour vision, contrast sensitivity). Signs: optic disc oedema/pallor, RAPD+, central scotoma with inferior arcuate defects. [6]
- Multiple sclerosis: Optic neuritis: ↓VA, ↓colour vision, unilateral eye pain, optic atrophy on fundoscopy, RAPD +ve [7]. Typically acute, but recurrent episodes can lead to chronic optic atrophy and permanent visual loss.
- Neuromyelitis optica spectrum disorder (NMOSD): "neuro" = nerve, "myelitis" = spinal cord inflammation, "optica" = optic; severe optic neuritis, often bilateral, with poor recovery.
- Ethambutol: optic neuritis (blurring of vision, scotoma, worsened colour discrimination) [8] — this is dose-related and usually reversible if detected early. Mechanism: inhibition of lysosomal function in retinal ganglion cells.
- Tobacco-alcohol amblyopia: bilateral optic neuropathy from combined nutritional deficiency (B12, folate) and direct toxic effects.
- Methanol poisoning: formic acid (metabolite) directly toxic to retinal ganglion cells and optic nerve.
The GC lecture framework organises chronic visual loss by anatomical site:
| Category | Conditions | Red Reflex |
|---|---|---|
| Cloudy Ocular Media | Corneal opacity, Cataract, Vitreous opacity | ↓ or absent |
| Retinal Disorders | Diabetic retinopathy, ARMD, Retinitis pigmentosa, Myopic macular degeneration, Epiretinal membrane | Normal (unless vitreous haemorrhage) |
| Optic Nerve | Glaucoma, Compressive optic neuropathy, Toxic optic neuropathy | Normal |
Key Clinical Pearl
The red reflex is your first triage tool. If the red reflex is diminished or absent, the problem is in the media (cornea, lens, or vitreous). If the red reflex is normal, the problem is in the retina or optic nerve — you need fundoscopy and visual field testing to distinguish.
6. Clinical Features
6.1 Symptoms
| Pattern | Suggests | Pathophysiological Basis |
|---|---|---|
| Painless, gradual, bilateral central blur | Cataract (most common), bilateral ARMD | Symmetric lens opacification or bilateral macular degeneration |
| Glare, especially at night | Cataract (particularly cortical or posterior subcapsular) | Irregular lens surface scatters incoming light |
| Myopic shift | Nuclear sclerotic cataract | Increasing refractive index of hardened nucleus bends light more → image focused in front of retina (myopia) [3] |
| Gradual peripheral VF loss | Glaucoma, retinitis pigmentosa | Glaucoma: arcuate nerve fibre bundle loss from optic disc; RP: rod photoreceptor death in mid-periphery first |
| Central scotoma / metamorphopsia | ARMD (wet > dry), macular oedema | Distortion of macular photoreceptor alignment by subretinal fluid/drusen/CNV |
| Night blindness (nyctalopia) | Retinitis pigmentosa, vitamin A deficiency | Rod photoreceptors (responsible for scotopic vision) are damaged first |
| Bitemporal VF loss / bumping into things on the side | Pituitary tumour compressing optic chiasm [5] | Nasal retinal fibres (carrying temporal VF information) cross at the chiasm and are compressed first |
| Painless, unilateral gradual vision loss | Unilateral cataract, unilateral glaucoma, compressive optic neuropathy, chronic optic neuritis | Asymmetric disease process |
| Symptom | Condition | Pathophysiological Basis |
|---|---|---|
| Floaters | Vitreous haemorrhage (PDR), posterior vitreous detachment | Blood or vitreous debris casting shadows on retina |
| Haloes around lights | Chronic angle-closure glaucoma, cataract | Corneal oedema (from ↑IOP) causes light diffraction; lens opacification also causes light scatter |
| Headache (dull, frontal/temporal) | Chronic glaucoma, pituitary tumour | Raised IOP causes referred pain via trigeminal V1; pituitary tumour stretches the diaphragma sellae |
| Eye/retroocular discomfort with gritty or FB sensation, excessive tearing | Graves' ophthalmopathy [6] | Proptosis → corneal exposure → reflex tearing; EOM inflammation → retroorbital ache |
| Diplopia | Graves' ophthalmopathy (most commonly affects IR > MR > SR > LPS > LR) [6] | EOM infiltration and fibrosis → restricted movement |
| Difficulty reading / near vision loss | Posterior subcapsular cataract, presbyopia, macular disease | PSC is directly in the visual axis and worsens with miosis (accommodation for near); macular disease impairs fine central discrimination |
- Difficulty driving (especially at night — glare from cataract, VF loss from glaucoma)
- Difficulty reading (macular disease, PSC cataract)
- Falls/accidents (peripheral VF loss — glaucoma, RP)
- Social withdrawal, depression (any severe visual loss)
6.2 Signs
VA tested with Snellen's chart, expressed as d/D where d = distance at which patient is reading chart, D = distance at which patient is expected to be able to read chart. Refractive error should be corrected by pinhole. If VA < 6/120 (can't read first row): can patient count fingers? If no, can patient detect movement? If no, can patient respond to light? [9]
- Pinhole testing is crucial: if VA improves with a pinhole, the problem is likely refractive (including cataract causing refractive change). If VA does NOT improve with pinhole, the problem is in the retina, optic nerve, or visual pathway.
- This is because a pinhole eliminates peripheral, unfocused rays and only allows a narrow, paraxial beam through — effectively bypassing any refractive error or media opacity (to a degree).
High Yield Exam Point
If VA improves with pinhole → refractive error / media opacity (e.g. cataract). If VA does NOT improve with pinhole → retinal or optic nerve pathology. This is a classic OSCE and MCQ discriminator.
- Relative Afferent Pupillary Defect (RAPD) — tested with the swinging flashlight test:
- The affected eye has reduced afferent input → when light swings to the affected eye, BOTH pupils paradoxically dilate (because the consensual response from the normal eye was stronger than the direct response from the affected eye).
- RAPD is present in: optic neuritis, CRAO, advanced glaucoma (asymmetric), compressive optic neuropathy. [6][7]
- RAPD is NOT caused by cataract (media opacity reduces light equally to both rods/cones but does not impair the afferent pathway proportionally enough to cause RAPD). This is a classic exam trap.
- RAPD is NOT caused by macular disease unless very severe and asymmetric (the macula contributes relatively little to the overall pupil light reflex compared to the much larger peripheral retina).
| Finding | Interpretation |
|---|---|
| Absent/diminished red reflex | Media opacity: corneal opacity, cataract, vitreous haemorrhage |
| Black opacity obscuring iris detail | Corneal opacity |
| Black opacity obscuring retinal detail but iris visible | Cataract |
| Normal red reflex | Media is clear; pathology is in retina, optic nerve, or visual pathway |
| Condition | Slit-Lamp Findings |
|---|---|
| Cataract | Nuclear sclerosis (yellow-brown lens nucleus), cortical spokes, posterior subcapsular plaque |
| Chronic angle closure | Shallow anterior chamber (van Herick grading), peripheral anterior synechiae, iris bombé |
| Rubeosis iridis | New abnormal vessels on iris surface → in PDR or CRVO [4] |
| Pseudoexfoliation syndrome | White flaky material on anterior lens capsule and pupil margin; associated with OAG |
This is the most information-rich examination for chronic visual loss:
| Condition | Fundoscopic Findings | Pathophysiological Basis |
|---|---|---|
| Diabetic retinopathy | Dot-blot haemorrhages (microaneurysm rupture), hard exudates (lipoprotein leakage), cotton wool spots (nerve fibre layer infarcts), venous beading, IRMA, neovascularization (PDR) [4] | See DR pathophysiology above |
| ARMD (dry) | Drusen (yellow deposits), RPE changes, geographic atrophy | Metabolic waste accumulation under RPE |
| ARMD (wet) | Subretinal fluid, haemorrhage, hard exudates at macula, CNV membrane, disciform scar (end-stage) | CNV leaks fluid and blood under retina |
| Glaucoma | Optic disc cupping (↑cup:disc ratio > 0.5, or asymmetry > 0.2), notching (focal rim loss, especially inferior/superior), disc haemorrhage, nerve fibre layer defects, nasal displacement of vessels | RGC axon loss → tissue loss at disc rim → cup enlarges |
| Retinitis pigmentosa | Bone-spicule pigmentation (mid-periphery), arteriolar attenuation, waxy pallor of disc | RPE cell migration into retina after photoreceptor death; vessel loss following retinal atrophy |
| Optic atrophy (chronic optic neuritis, compressive neuropathy, post-glaucomatous) | Pale optic disc (loss of capillaries on disc surface due to axonal loss) | Axonal death → Wallerian degeneration → loss of disc vascularity → pallor |
| Graves' optic neuropathy | Optic disc oedema/pallor, RAPD+ [6] | Apical crowding → compressive optic neuropathy |
| Papilloedema (chronic) | Bilateral disc swelling → eventually atrophic pallor if longstanding | Raised ICP transmitted along optic nerve sheath → axoplasmic flow stasis → disc oedema |
| Hypertensive retinopathy (chronic) | Arteriolar narrowing, AV nipping, copper/silver wiring, flame haemorrhages, cotton wool spots | Chronic HTN → arteriolar wall thickening → compromised retinal perfusion |
| Pattern | Condition |
|---|---|
| Arcuate scotoma (Bjerrum scotoma) | Glaucoma |
| Central scotoma | Macular disease, optic neuritis, toxic optic neuropathy |
| Peripheral constriction ("tunnel vision") | Retinitis pigmentosa, end-stage glaucoma |
| Bitemporal hemianopia | Chiasmal compression (pituitary tumour) [5] |
| Homonymous hemianopia | Post-chiasmal lesion (stroke, tumour) |
| Altitudinal defect | Ischaemic optic neuropathy (NAION), branch retinal artery/vein occlusion |
- Measured by Goldmann applanation tonometry (gold standard), non-contact tonometry ("air puff"), or iCare rebound tonometry.
- Normal: 10–21 mmHg.
- ↑IOP alone does not diagnose glaucoma — it is one risk factor. Conversely, normal IOP does not exclude glaucoma (NTG).
- Very high IOP ( > 40 mmHg) suggests acute angle closure (but this is acute, not chronic visual loss).
- Direct visualisation of the drainage angle using a goniolens on the slit lamp.
- Classifies angle as open or closed (Shaffer grading).
- Essential for distinguishing POAG from PACG and identifying secondary causes (neovascularization, synechiae, pigment dispersion).
7. Special Considerations in the Clinical Approach
- Refractive error (myopia, hyperopia, astigmatism, presbyopia) is the most common cause of impaired vision worldwide but is NOT considered "pathological" chronic visual loss because it is correctable with spectacles/contact lenses.
- The clinical approach always starts with best-corrected visual acuity (BCVA) — i.e., VA after correcting refractive error.
- If BCVA is reduced, there is an underlying pathological cause.
| Drug | Eye Effect | Mechanism |
|---|---|---|
| Ethambutol | Optic neuritis (scotoma, ↓colour vision) [8] | Mitochondrial toxicity in RGCs |
| Systemic corticosteroids | Posterior subcapsular cataract, steroid-induced glaucoma | Lens epithelial changes; ↑IOP via ↑aqueous outflow resistance in trabecular meshwork |
| Chloroquine / Hydroxychloroquine | Bull's eye maculopathy (irreversible) | Accumulates in RPE → toxicity to photoreceptors |
| Amiodarone | Corneal verticillata (vortex keratopathy), optic neuropathy (rare) | Drug deposits in corneal epithelium |
| Tamoxifen | Crystalline maculopathy, cataract | Intracellular accumulation in retina |
| Vigabatrin | Peripheral VF constriction (irreversible) | GABA-mediated retinal toxicity |
Drug-Induced Vision Loss
Always take a thorough drug history in chronic visual loss. Ethambutol (anti-TB) requires baseline visual acuity and colour vision testing before starting, with regular monitoring [8]. Hydroxychloroquine (used in SLE, RA) requires annual retinal screening after 5 years of use (or from the start if high-risk).
| Condition | Who to Screen | How Often | Method |
|---|---|---|---|
| Diabetic retinopathy | All T2DM at diagnosis; T1DM ≥ 5 years from diagnosis (or at puberty/≥ 10 years) [4] | Annual | Dilated fundoscopy or fundus photography |
| Glaucoma | Those with RFs (FHx, high myopia, ↑IOP on screening, age > 40) | Every 1–2 years | IOP, optic disc assessment, VF |
| HCQ retinal toxicity | All patients on long-term hydroxychloroquine | Annual after 5 years (or sooner if high risk) | OCT macula, VF 10-2, fundus autofluorescence |
| Ethambutol toxicity | All patients starting ethambutol | Baseline and monthly during treatment [8] | VA, colour vision (Ishihara plates) |
A systematic approach to chronic visual loss in the clinic:
- History: Onset (truly gradual?), laterality, central vs peripheral, associated symptoms (pain, redness, floaters, metamorphopsia, night blindness, haloes), functional impact, drug history, PMHx (DM, HTN, autoimmune), FHx (glaucoma, RP, ARMD).
- Visual acuity with Snellen chart → pinhole correction → determines if refractive or pathological.
- Pupil examination: RAPD (optic nerve pathology).
- Red reflex: diminished → media opacity; normal → retinal or optic nerve.
- Anterior segment (slit lamp): lens clarity, anterior chamber depth, rubeosis, pseudoexfoliation.
- IOP measurement: raised → glaucoma suspect; normal → does not exclude NTG.
- Gonioscopy: open vs closed angle.
- Dilated fundoscopy: retina (DR, ARMD, RP), optic disc (cupping for glaucoma, pallor for atrophy, swelling for papilloedema), vessels.
- Visual field testing: pattern of VF loss localises the lesion.
- Further investigations as indicated (OCT, FFA, neuroimaging, etc.) — to be discussed in the diagnostic workup section.
High Yield Summary
Chronic visual loss = progressive, insidious decline in VA and/or VF.
Three anatomical categories (from GC lecture framework):
- Cloudy media (↓red reflex): cataract (most common globally), corneal opacity, vitreous opacity.
- Retinal disease (normal red reflex): DR (commonest cause of visual loss in DM), ARMD (commonest cause of irreversible central vision loss in elderly), retinitis pigmentosa.
- Optic nerve (normal red reflex, RAPD+): glaucoma (leading cause of irreversible blindness worldwide), compressive optic neuropathy (pituitary tumour → bitemporal hemianopia), toxic (ethambutol, methanol).
Key HK-relevant points:
- NTG is more common than high-pressure POAG in Chinese populations.
- PACG is more common in East Asians (shallow anterior chamber, hyperopic eyes).
- Nuclear sclerotic cataract causes myopic shift (AOS scenario: increasing myopia in an elderly patient).
- DR screening: annual dilated eye exam from T2DM diagnosis, T1DM after 5 years.
- DMO is the commonest cause of vision loss in DM patients.
- Ethambutol → optic neuritis; monitor VA and colour vision.
- RAPD is NOT caused by cataract (classic exam pitfall).
- Pinhole improves VA in refractive error/media opacity; does NOT improve VA in retinal/optic nerve disease.
Active Recall - Chronic Visual Loss
[1] Ryan Ho Opthalmology, pp. 4, 43 (Approach to Gradual Visual Loss) [2] GC 122. Chronic Visual Loss.pdf (GC lecture slides) [3] AOS - Ophthalmology.pdf / AOS - Ophthalmology Annotated.pdf (PBL Chronic Visual Loss Scenarios) [4] Ryan Ho Endocrine, pp. 94–95 (Diabetic Retinopathy and Chronic Diabetic Complications); Block A - Deterioration of eyesight in a diabetic patient: diabetic complications.pdf [5] Block A - I keep on bumping into people on my side: pituitary tumours; hypopituitarism.pdf [6] Ryan Ho Endocrine, pp. 26–27 (Graves' Ophthalmopathy) [7] Maksim Medicine Notes, p. 261 (MS and Optic Neuritis) [8] Gen Clerk Anaes + Microbiology Summary, p. 41 (Ethambutol toxicity) [9] Ryan Ho Fundamentals, p. 89; Ryan Ho Neurology, p. 11 (Visual Acuity and Approach to Vision Loss)
Differential Diagnosis of Chronic Visual Loss
The differential diagnosis of chronic visual loss is built on the same anatomical framework introduced earlier — front to back (media → retina → optic nerve → visual pathway). The power of this approach is that bedside findings systematically narrow the list before any investigation is ordered.
Common diagnoses for chronic visual loss: Cataract, Glaucoma, Diabetic retinopathy / Diabetic macular oedema, Age-related macular degeneration. Take a thorough history. Detailed physical exam. Be systematic, think from front to back. [2]
This GC take-home message tells you exactly what the examiners want: a structured, anatomical approach, not a random list.
Before listing causes, understand the three clinical questions that narrow the differential at the bedside:
| Bedside Question | How to Answer It | What It Tells You |
|---|---|---|
| 1. Is the red reflex normal? | Direct ophthalmoscope at arm's length | Diminished/absent → media opacity (cornea, lens, vitreous). Normal → retina or optic nerve. |
| 2. Does VA improve with pinhole? | Pinhole occluder | Improves → refractive/media component. Does not improve → retinal or neural pathology. |
| 3. Is there RAPD? | Swinging flashlight test | Present → optic nerve (or very severe, asymmetric retinal disease). Absent → media or mild/symmetric retinal disease. |
These three observations alone can place a patient into one of the three anatomical compartments before any slit-lamp or fundoscopy is performed.
2. Differential Diagnosis Organised by Anatomical Site
| Condition | Key Discriminating Features | Why It Causes Gradual Loss |
|---|---|---|
| Cataract | Painless ↓vision with glare, often myopic shift (nuclear type). ↓Red reflex obscures retina but NOT iris. Leukocoria in advanced cases. [1] | Lens proteins denature gradually over months–years → progressive opacification → progressive light scatter |
| Corneal opacity | ↓Red reflex obscures iris detail. History of prior trauma, surgery, chronic uveitis, or interstitial keratitis (syphilis/TB). Band keratopathy (calcium deposition in Bowman's layer — seen in chronic uveitis, hypercalcaemia). [1] | Corneal scarring/oedema builds slowly; endothelial cell loss is irreversible |
| Vitreous opacity | Floaters, ↓red reflex proportional to amount of blood/debris. Usually subacute to acute but can be insidious (e.g. recurrent minor vitreous haemorrhages in PDR). [1] | Recurrent small bleeds from neovascularization → chronic vitreous haze |
Exam Discriminator: Corneal vs Lens Opacity
On slit-lamp examination: corneal opacity is anterior to the iris → it obscures iris detail. Cataract is posterior to the iris → you can still see the iris but the retinal view (red reflex) is diminished. This distinction is a classic OSCE question.
| Condition | Key Discriminating Features | Why It Causes Gradual Loss |
|---|---|---|
| Diabetic retinopathy (DR) | DM history. Often asymptomatic until late. Fundoscopy: dot-blot haemorrhages, hard/soft exudates, venous beading, IRMA ± neovascularization. [1][4] DMO can occur at any stage and is commonest cause of vision loss in DM patients [4]. | Microangiopathy and ischaemia progress over years; macular oedema develops insidiously |
| Age-related macular degeneration (ARMD) | Age > 50. Central vision loss ± metamorphopsia. Amsler grid abnormal. Drusen, RPE changes (dry); subretinal fluid/haemorrhage (wet). [1] | Dry: drusen accumulation and RPE atrophy over years. Wet: CNV can cause subacute deterioration (days–weeks) |
| Retinitis pigmentosa (RP) | Young adult, night blindness → tunnel vision. FHx. Bone-spicule pigment, arteriolar attenuation, waxy disc pallor. | Genetic rod photoreceptor degeneration → years to decades of progressive VF constriction |
| Epiretinal membrane / macular hole | Metamorphopsia, ↓central VA. OCT diagnostic. | Fibrocellular membrane contracts over macula → gradual distortion |
| Chronic central serous chorioretinopathy (CSC) | Typically 30–50y male, type A personality. Central blurring, micropsia, metamorphopsia. Serous retinal detachment on OCT/FFA. | Recurrent RPE dysfunction → chronic subretinal fluid |
| Myopic macular degeneration | High myopia ( > −6D). Long axial length. Lacquer cracks, myopic CNV, posterior staphyloma, macular atrophy. | Mechanical stretching of retina/RPE/choroid in elongated globe |
DR Can Present Acutely AND Chronically
Visual loss from diabetic retinopathy can be secondary to: macular oedema (NPDR — gradual), pre-retinal or vitreous haemorrhage (from neovascularization — acute), traction retinal detachment (PDR — acute/subacute), neovascular glaucoma (PDR — subacute). [10] This means DR sits on a spectrum — one patient may present with chronic blurred vision from DMO and then suddenly lose vision from a vitreous haemorrhage. Always think about both timescales.
| Condition | Key Discriminating Features | Why It Causes Gradual Loss |
|---|---|---|
| Glaucoma (POAG / NTG / chronic PACG) | Peripheral VF loss (arcuate scotoma → nasal step → tunnel vision). Central VA preserved until late. Optic disc cupping (↑C:D ratio). IOP may or may not be raised (NTG). Gonioscopy distinguishes open vs closed angle. [1] | Progressive retinal ganglion cell loss at the lamina cribrosa over months–years |
| Compressive optic neuropathy | Bitemporal hemianopia (pituitary tumour) [5]; unilateral progressive VF loss (meningioma, craniopharyngioma). Optic disc pallor. Endocrine symptoms if functional tumour. [5] | Slow tumour growth compresses optic nerve/chiasm gradually |
| Graves' compressive optic neuropathy | Slowly progressive ↓vision (esp colour vision, contrast sensitivity). Optic disc oedema/pallor, RAPD+. Central scotoma with inferior arcuate defects. [6] Proptosis, lid signs, ophthalmoplegia. | Oversized recti + orbital fat → apical crowding → compressive optic neuropathy [6] |
| Toxic / nutritional optic neuropathy | Bilateral, symmetrical central scotomas. Drug history (ethambutol: scotoma, ↓colour discrimination [8]; isoniazid; methanol). Nutritional history (B12, folate deficiency — tobacco-alcohol amblyopia). | Cumulative toxin exposure or nutritional deficiency damages RGCs over weeks–months |
| Chronic papilloedema | Bilateral disc swelling → secondary optic atrophy. Headache worse on waking/straining, transient visual obscurations, VF constriction. Raised ICP causes. | Chronic ICP elevation → axoplasmic flow stasis → progressive axonal damage at the disc |
| Hereditary optic neuropathies | Leber's hereditary optic neuropathy (LHON): young male, sequential bilateral central vision loss. Maternal inheritance (mitochondrial). Dominant optic atrophy (Kjer disease): childhood onset, bilateral, insidious. | Mitochondrial dysfunction in RGCs → slow degeneration |
While post-chiasmal lesions typically present acutely (e.g. stroke), slow-growing lesions can cause chronic visual field loss:
| Condition | Key Discriminating Features |
|---|---|
| Slow-growing tumour (glioma, meningioma, metastasis) | Homonymous hemianopia or quadrantanopia. Other neurological signs depending on location. |
| Chronic hydrocephalus | Bilateral VF constriction from chronic papilloedema → optic atrophy. |
The following mermaid diagram illustrates the bedside approach to narrowing the differential:
The "Big Four" of chronic visual loss — Cataract, Glaucoma, DR, and ARMD — are what the GC lecture explicitly highlights as take-home messages [2]. Being able to rapidly distinguish between them is essential for exams and clinical practice.
| Feature | Cataract | Glaucoma (POAG/NTG) | Diabetic Retinopathy | ARMD |
|---|---|---|---|---|
| Age | Any, usually > 60 | Usually > 40 | Any DM patient | > 50 |
| Laterality | Often bilateral (asymmetric) | Usually bilateral (asymmetric) | Bilateral | Usually bilateral |
| Pain | Painless | Painless (chronic) | Painless | Painless |
| Central VA | ↓ early | Preserved until late | ↓ if DMO or vitreous haemorrhage | ↓ early (central vision affected) |
| VF defect | Generalised blur/haze | Arcuate → nasal step → tunnel | Not until advanced | Central scotoma |
| Red reflex | ↓ | Normal | Normal (unless VH) | Normal |
| RAPD | No | Yes (if asymmetric/advanced) | Rare (unless severe) | No (unless very severe) |
| Key fundoscopy | Not visualised (lens opaque) | Disc cupping, ↑C:D ratio | Dot-blot, exudates, NV | Drusen, RPE changes, CNV |
| Key Ix | Slit-lamp | IOP, VF, OCT RNFL, gonioscopy | Fundus photo, OCT macula, FFA | OCT macula, FFA/ICGA |
| Improves with pinhole? | Yes (partially) | No | No | No |
Why Glaucoma Preserves Central VA Until Late
The papillomacular bundle (the group of RGC axons serving the macula) is relatively resistant to glaucomatous damage — probably because these fibres are smaller, more numerous, and positioned centrally at the disc where the lamina cribrosa is thickest and most supportive. So the arcuate fibres (supero-temporal and infero-temporal) die first, producing peripheral VF loss, while central acuity is preserved until very late. This is why patients with glaucoma often present only when vision is severely compromised — they don't notice the peripheral loss.
Some causes of chronic visual loss are treatable emergencies disguised as gradual complaints, or have systemic implications that change management:
| Condition | Why It Must Not Be Missed |
|---|---|
| Pituitary tumour | Compressive optic neuropathy is reversible with surgical decompression if caught early. Also need to assess for hypopituitarism and hormone hypersecretion. "Pituitary tumors can present with visual loss (optic chiasm involvement), functional symptoms (hyper/hyposecretion), or incidentally." [5] |
| GCA-related optic neuropathy | Anterior ischaemic optic neuropathy from GCA causes irreversible visual loss. Bilateral involvement occurs in ~50% if untreated. Must start high-dose steroids immediately upon clinical suspicion — do not wait for biopsy. [11] |
| Chronic angle closure | Intermittent angle closure → peripheral anterior synechiae → chronic IOP elevation → optic neuropathy. May present as chronic headache + gradual VF loss. Prophylactic laser PI prevents acute crisis. |
| Neovascular glaucoma (from PDR / CRVO) | Rubeosis iridis → neovascularization of angle → secondary angle closure → rapidly progressive glaucoma. [4] Requires urgent PRP ± anti-VEGF. |
| Methanol poisoning | Formic acid → inhibits cytochrome oxidase → tissue hypoxia + ocular toxicity. "Snowstorm-like" blurry vision. Fundoscopy shows hyperaemia or disc pallor. [12] May present subacutely. Treat with fomepizole/ethanol + haemodialysis. |
6. Special Differential Considerations by Patient Demographics
- High myopia → myopic macular degeneration (very common in HK)
- Retinitis pigmentosa (night blindness, FHx)
- Leber's hereditary optic neuropathy (young males, maternal inheritance)
- Keratoconus (progressive corneal thinning → irregular astigmatism → ↓VA; often presents in teens/20s)
- Juvenile open-angle glaucoma (rare, strongly genetic)
- Diabetic retinopathy / DMO (the most common answer in this demographic)
- Cataract (DM accelerates cataract formation via the polyol pathway)
- Neovascular glaucoma (from PDR)
- Cranial nerve palsy (mononeuritis multiplex → diplopia rather than true ↓VA, but patients may describe "visual difficulty")
- Cataract (most common overall)
- ARMD (most common cause of irreversible central vision loss)
- Glaucoma (most common cause of irreversible blindness)
- Chronic angle closure (especially in hyperopic, East Asian, elderly female patients [3])
- GCA-related AION (rare but devastating; always consider in elderly with new headache + visual symptoms) [11]
| History Clue | Top Differential | Reasoning |
|---|---|---|
| "Everything looks yellow/brown" | Nuclear sclerotic cataract | Yellowed lens acts as a filter |
| "I keep bumping into people on my side" | Pituitary tumour (bitemporal hemianopia) [5] | Nasal fibres (temporal VF) compressed at chiasm |
| "Straight lines look wavy" | Wet ARMD, DMO, epiretinal membrane | Macular photoreceptor displacement by subretinal fluid/membrane |
| "I can't see at night" | Retinitis pigmentosa, vitamin A deficiency, nuclear cataract | Rod dysfunction (RP, vit A) or lens scatter worsened in dim light |
| "My peripheral vision is shrinking" | Glaucoma, RP, chronic papilloedema | Arcuate RGC loss (glaucoma); rod loss (RP); axonal damage (papilloedema) |
| "I see haloes around lights" | Chronic angle closure, cataract | Corneal oedema (↑IOP) → light diffraction; lens opacity → scatter |
| Drug history: ethambutol | Ethambutol optic neuritis [8] | Dose-dependent RGC mitochondrial toxicity |
| Drug history: corticosteroids | Steroid-induced POAG, posterior subcapsular cataract | ↑Aqueous outflow resistance; lens epithelial changes |
| "I have Graves' disease" | Graves' compressive optic neuropathy [6] | EOM/fat expansion → apical crowding |
High Yield Summary — Differential Diagnosis of Chronic Visual Loss
- Use the "front-to-back" anatomical framework: Media (↓red reflex) → Retina (fundoscopy abnormal) → Optic nerve (RAPD, disc pallor/cupping) → Visual pathway (homonymous VF defects).
- The "Big Four" (GC lecture) = Cataract, Glaucoma, DR/DMO, ARMD [2].
- Bedside triage: Red reflex (media vs not), pinhole (refractive vs neural), RAPD (optic nerve), VF pattern (localises lesion).
- Must-not-miss: Pituitary tumour (reversible with surgery), GCA (urgent steroids prevent bilateral blindness), neovascular glaucoma (urgent PRP), methanol (fomepizole + dialysis).
- HK-specific: NTG predominates over high-pressure POAG; PACG more common in Chinese; high myopia → myopic macular degeneration; DM prevalence high → DR screening critical.
- Cataract does NOT cause RAPD — this is the single most tested discriminator.
Active Recall - Differential Diagnosis of Chronic Visual Loss
References
[1] Senior notes: Ryan Ho Opthalmology, p. 43 (Approach to Gradual Visual Loss) [2] Lecture slides: GC 122. Chronic Visual Loss.pdf, p. 44 (Take home messages) [3] AOS material: AOS - Ophthalmology.pdf, p. 3 (PBL Chronic Visual Loss Scenario 1); AOS - Ophthalmology Annotated.pdf, p. 3 [4] Senior notes: Ryan Ho Endocrine, pp. 94–95 (Diabetic Retinopathy and Chronic Diabetic Complications) [5] Senior notes: Block A - I keep on bumping into people on my side: pituitary tumours; hypopituitarism.pdf, p. 1 [6] Senior notes: Ryan Ho Endocrine, pp. 26–27 (Graves' Ophthalmopathy — compressive optic neuropathy) [8] Senior notes: Gen Clerk Anaes + Microbiology Summary, p. 41 (Ethambutol toxicity) [10] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), p. 1510 (Diabetic retinopathy) [11] Senior notes: Ryan Ho Rheumatology, p. 95 (GCA and PMR); Block A - Rheumatology Interactive Tutorial, p. 1 [12] Senior notes: Ryan Ho Chemical Path, p. 41 (Methanol toxicity)
Diagnostic Criteria, Diagnostic Algorithm and Investigations for Chronic Visual Loss
Chronic visual loss is a presenting complaint, not a single disease. There is therefore no single set of diagnostic criteria for "chronic visual loss" itself. Instead, the clinician uses a systematic bedside algorithm to narrow the anatomical compartment, then applies disease-specific diagnostic criteria for the underlying cause (e.g. glaucoma, DR, ARMD). This section covers:
- The bedside diagnostic algorithm (how to localise the problem).
- Disease-specific diagnostic criteria for the Big Four and other important causes.
- Investigation modalities with key findings and interpretation.
The GC lecture framework is explicit: Be systematic, think from front to back. [2] This means: for every patient with chronic visual loss, you walk through the eye compartment by compartment — anterior to posterior — using bedside tests that are available in any clinic.
Approach to gradual visual loss — History: pattern of visual loss (gradual blurring, distortion = maculopathy, central scotoma = maculopathy or optic neuropathy, constricting VF = chronic glaucoma or RP), other visual disturbances (glares = cataract, rainbow haloes = glaucoma), pain (chronic dull eye pain may occur in glaucoma), systemic diseases (DM, HTN). P/E: VA and VF (pattern of visual loss), pupil exams and RAPD (RAPD = optic nerve pathology usually), red reflex (lost in ↑ocular media opacity), fundoscopy (for posterior eye pathologies). [1]
3. Disease-Specific Diagnostic Criteria
There are no formal "diagnostic criteria" for cataract — it is a clinical diagnosis made by slit-lamp examination.
Diagnostic features:
- Painless loss of vision with glare and often myopic shift [1]
- ↓Red reflex with black opacification that obscures underlying retina but not the iris [1]
- Slit-lamp biomicroscopy: direct visualisation of lens opacification (nuclear sclerosis, cortical spokes, posterior subcapsular plaque)
- VA improves with pinhole (partially — because light scatter from the cataract is reduced when only a narrow beam enters)
- No RAPD (the afferent neural pathway is intact)
Grading: Lens Opacities Classification System III (LOCS III) — grades nuclear opalescence/colour, cortical opacity, and posterior subcapsular opacity on standardised photographs. Used mainly for research; clinical practice relies on slit-lamp description and functional impact.
When to Suspect Cataract Is NOT the Only Problem
If VA does NOT improve at all with pinhole in a patient with visible cataract, suspect a co-existing retinal or optic nerve problem behind the cataract (e.g. DM patient with cataract + macular oedema). The cataract may be obscuring fundoscopy → order B-scan ultrasonography to check the posterior segment.
Glaucoma is diagnosed by the triad of:
- Characteristic optic disc changes (cupping)
- Corresponding visual field defects
- ± elevated IOP (not required for NTG)
Optic nerve degeneration that is usually due to increased intraocular pressure. Can be open-angle (usually chronic) or closed-angle (usually acute). Usually asymptomatic in early stages and associated with gradual constriction of VF. Fundoscopy shows pathologically cupped optic disc ( > 0.4, ↑ in larger discs). Goldmann tonometry shows ↑IOP, usually in the range of 22–40 mmHg. [1]
Key diagnostic features on optic disc examination:
ISNT Rule — In a healthy, non-glaucomatous eye, the thickness of the neuroretinal rim decreases in a specific directional hierarchy: Inferior ≥ Superior ≥ Nasal ≥ Temporal. Violation of this rule (e.g. inferior rim thinner than temporal) suggests glaucomatous damage. [13]
| Finding | Significance |
|---|---|
| ↑Cup-to-disc (C:D) ratio > 0.5 | Suspicious; must compare both eyes |
| Asymmetry of C:D ratio > 0.2 between eyes | Highly suspicious |
| Focal notching of neuroretinal rim (superior or inferior) | Early glaucoma sign — arcuate fibre damage |
| Disc haemorrhage (Drance haemorrhage) | Flame-shaped at disc margin; predicts future VF loss |
| RNFL defects | Visible as wedge-shaped darkening of the peripapillary retina |
| Bayoneting of vessels | Vessels break and re-emerge at disc edge due to deep cupping |
| Laminar dot sign | Deep cupping exposes lamina cribrosa pores |
Differentiating pathological from physiological cupping:
How to differentiate glaucoma from physiological cupping? — (1) ISNT rule violated in glaucoma; (2) Visual field assessment shows corresponding defects in glaucoma; (3) Disc size matters — large discs naturally have larger cups; (4) OCT RNFL thickness is reduced in glaucoma. [13]
DR is diagnosed clinically by dilated fundoscopy and classified by the ETDRS classification:
Classification based on Early Treatment Diabetic Retinopathy Study (ETDRS):
- Mild NPDR: only microaneurysms (earliest sign)
- Moderate NPDR: more than just aneurysms but less than severe NPDR
- Severe NPDR — 4-2-1 rule (52% will progress to PDR): > 20 intraretinal haemorrhages in each 4 quadrants; OR definite venous beading in ≥ 2 quadrants; OR prominent IRMA in ≥ 1 quadrant
- Very severe NPDR (75% will progress to PDR): ≥ 2 of criteria in severe NPDR, NO evidence of neovascularization
- Proliferative DR: retinal neovascularization ± preretinal or vitreous haemorrhage; rubeosis iridis ± rubeotic glaucoma [4][14]
Clinically significant macular oedema (CSME):
- Thickening of retina ≤ 500 μm from macular centre; OR
- Hard exudates and adjacent retinal thickening ≤ 500 μm from macular centre; OR
- Zone of retinal thickening ≥ 1 disc area in size located ≤ 1 disc diameter from centre of macula [14]
High Yield: The 4-2-1 Rule
This is a favourite exam question. The 4-2-1 rule defines severe NPDR, which has a > 50% risk of progressing to PDR within one year. Any one of the three criteria is sufficient: 4 quadrants of haemorrhages, 2 quadrants of venous beading, 1 quadrant of IRMA. This is the stage where you consider pan-retinal photocoagulation.
Diagnosed clinically by fundoscopy + OCT. The Age-Related Eye Disease Study (AREDS) classification is widely used:
| AREDS Category | Findings |
|---|---|
| 1 (No AMD) | No or few small drusen ( < 63 μm) |
| 2 (Early AMD) | Many small drusen or few intermediate drusen (63–124 μm), or RPE abnormalities |
| 3 (Intermediate AMD) | Extensive intermediate drusen, ≥ 1 large drusen ( > 125 μm), or geographic atrophy not involving fovea |
| 4 (Advanced AMD) | Geographic atrophy involving fovea (dry) OR choroidal neovascularisation (wet) |
Wet ARMD is confirmed by fluorescein angiography (FFA) or indocyanine green angiography (ICGA) showing the choroidal neovascular membrane, and by OCT showing subretinal/intraretinal fluid.
Diagnostic criteria for GCA — ACR 1990: ≥ 3 of 5 criteria: (1) Onset ≥ 50 years; (2) New headache; (3) Abnormalities of temporal artery at clinical examination; (4) ↑ESR ( > 50 mm/h); (5) Abnormal findings on biopsy of temporal artery. [15]
This is primarily an acute visual loss condition but is included here because patients may present with subacute visual decline, amaurosis fugax episodes, or chronic headache with gradual visual field loss before catastrophic AION occurs.
McDonald diagnostic criteria — requires dissemination in space (T2 lesions in ≥ 2 of 4 MS-typical regions: periventricular, juxtacortical, infratentorial, spinal cord) AND dissemination in time (simultaneous presence of gadolinium-enhancing and non-enhancing lesions, or new lesion on follow-up MRI, or second clinical attack). [16]
4. Investigation Modalities — Key Findings and Interpretation
The investigations are best understood by what question they answer:
| Investigation | What It Answers | Key Findings | Interpretation |
|---|---|---|---|
| Snellen chart | How much central VA is lost? | d/D ratio; if < 6/9, suspect pathology | Pinhole correction → refractive/media; no correction → retinal/neural |
| Pinhole test | Is the VA loss refractive or pathological? | VA improves → refractive/cataract; does not → retina/ON | First-line triage tool |
| Colour vision (Ishihara plates) | Is there optic nerve dysfunction? | ↓Colour discrimination (especially red-green) | Disproportional dyschromatopsia relative to VA loss is characteristic of optic neuropathy [1] — because the papillomacular bundle (serving colour) is preferentially affected |
| Amsler grid | Is there macular pathology? | Wavy lines (metamorphopsia) or missing areas (scotoma) | Suggests ARMD, DMO, epiretinal membrane, CSR |
| Confrontation VF | Gross VF defect screening | Bitemporal hemianopia, homonymous hemianopia, altitudinal defect | Localises lesion anatomically; must be confirmed with formal perimetry |
| Swinging flashlight test | RAPD? | Paradoxical dilation when light swings to affected eye | Optic nerve pathology (or very severe asymmetric retinal disease). Not caused by cataract. |
| Red reflex | Media opacity? | Absent/diminished → media opacity | Corneal opacity obscures iris; cataract obscures retina |
| Direct ophthalmoscopy | Disc and macula appearance | Cupping, pallor, drusen, haemorrhages, exudates | Screening-level posterior segment exam |
| Application | Key Findings |
|---|---|
| Anterior segment | Cataract type and grade (nuclear, cortical, PSC); anterior chamber depth (van Herick — shallow = angle-closure risk); pseudoexfoliation material on lens/pupil margin; rubeosis iridis (new vessels on iris surface — PDR/CRVO) |
| With 90D/78D condensing lens | Dilated fundoscopy at the slit lamp — gold standard for retinal examination. Stereoscopic view allows assessment of macular thickening (CSME), optic disc cupping (3D view superior to direct ophthalmoscopy) |
| Gonioscopy (with goniolens) | Direct visualisation of the drainage angle. Shaffer grading: Grade 0 = closed, Grade 4 = wide open. Identifies peripheral anterior synechiae, neovascularization of angle, pigment dispersion. Essential for differentiating POAG from PACG. |
| Method | Principle | Considerations |
|---|---|---|
| Goldmann applanation tonometry (GAT) | Gold standard. Measures force needed to flatten (applanate) a standard 3.06 mm area of cornea | Affected by central corneal thickness (CCT): thin cornea → underestimates IOP (important in NTG diagnosis); thick cornea → overestimates. Normal IOP = 10–21 mmHg. |
| Non-contact tonometry ("air puff") | Screening tool; measures corneal deformation by air jet | Less accurate than GAT; good for screening only |
| iCare rebound tonometry | Portable probe bounces off cornea | Useful for children, uncooperative patients, community screening |
IOP Alone Does Not Diagnose or Exclude Glaucoma
A common student mistake: "IOP is 18 therefore no glaucoma." Normal-tension glaucoma has IOP within the normal range — you MUST assess the optic disc and visual field. Conversely, "ocular hypertension" (IOP > 21 without disc changes or VF loss) is a risk factor but not glaucoma.
- Measures CCT (normal ~540 μm in Chinese).
- Why it matters: Thin corneas ( < 510 μm) underestimate IOP by GAT → patient may have true IOP higher than measured → increased glaucoma risk. The Ocular Hypertension Treatment Study (OHTS) identified thin CCT as an independent risk factor for developing POAG.
- Thick corneas overestimate IOP → some patients labelled "ocular hypertension" actually have normal true IOP.
| Type | Method | Use |
|---|---|---|
| Humphrey Visual Field (HVF) | Automated static perimetry. Standard programs: 24-2 (glaucoma), 10-2 (macular/central diseases, HCQ toxicity) | Gold standard for glaucoma monitoring. Detects arcuate scotomas, nasal steps, generalised depression. |
| Goldmann perimetry | Manual kinetic perimetry | Better for neurological VF defects (hemianopias), peripheral VF (RP), uncooperative patients |
Key VF patterns and their diagnostic significance:
| VF Pattern | Condition | Why This Pattern? |
|---|---|---|
| Arcuate scotoma (Bjerrum) | Glaucoma | Arcuate nerve fibre bundles (from temporal retina arching over/under macula) are most vulnerable at the disc poles |
| Nasal step | Glaucoma | Asymmetric arcuate fibre loss above vs below the horizontal raphe |
| Paracentral scotoma | Early glaucoma (especially NTG) | NTG tends to affect central VF earlier than POAG |
| Central scotoma | Macular disease, optic neuritis, toxic optic neuropathy | Papillomacular bundle or foveal photoreceptor damage |
| Tunnel vision | End-stage glaucoma, retinitis pigmentosa | Glaucoma: only papillomacular bundle survives; RP: all peripheral rods dead |
| Bitemporal hemianopia | Chiasmal compression (pituitary tumour) [5] | Nasal fibres decussate at chiasm; compressed by suprasellar mass |
| Homonymous hemianopia | Post-chiasmal lesion (stroke, tumour) | Tract/radiation/cortex lesion |
| Altitudinal defect | NAION, branch retinal artery occlusion | Watershed ischaemia of the optic disc (superior/inferior); or sectoral retinal ischaemia |
OCT is the single most important ancillary investigation in modern ophthalmology — it provides cross-sectional imaging of the retina and optic nerve at near-histological resolution (~ 5–10 μm).
| Application | What It Shows | Clinical Use |
|---|---|---|
| OCT macula | Retinal layer thickness, intraretinal/subretinal fluid, drusen, RPE changes, epiretinal membrane, macular hole | Diagnoses DMO (retinal thickening), confirms wet ARMD (subretinal fluid/CNV), epiretinal membrane, macular hole |
| OCT RNFL (retinal nerve fibre layer) | RNFL thickness around the optic disc | Glaucoma: RNFL thinning (especially superior and inferior quadrants) = objective, quantitative measure of ganglion cell axon loss. Superior to clinical disc assessment for early glaucoma detection. |
| OCT ganglion cell analysis (GCA) | Macular ganglion cell-inner plexiform layer thickness | Early glaucoma detection; HCQ toxicity screening |
| OCT angiography (OCTA) | Non-invasive vascular imaging without dye | DR: microaneurysms, capillary non-perfusion, NV; ARMD: CNV detection |
For glaucoma: OCT of RNFL and visual field assessment are the two key investigations for confirming diagnosis and monitoring progression. [13]
Principle: Intravenous fluorescein dye is injected → serial photographs taken as dye transits through retinal and choroidal vasculature. Fluorescein fluoresces green under blue light → highlights vascular abnormalities.
| Finding | Interpretation | Condition |
|---|---|---|
| Microaneurysm hyperfluorescence | Tiny dots that leak fluorescein | DR |
| Capillary non-perfusion (dark areas) | Retinal ischaemia | Severe NPDR, PDR, CRVO |
| Neovascularization leakage | Profuse late leakage from abnormal vessels | PDR, wet ARMD |
| Macular oedema (petalloid pattern) | Flower-petal leakage at macula | DMO, post-operative (Irvine-Gass), uveitis |
| CNV membrane | Early hyperfluorescence with progressive leakage | Wet ARMD, myopic CNV |
| Window defect | Transmission hyperfluorescence (RPE atrophy allows choroidal fluorescence to be seen) | Dry ARMD with geographic atrophy |
When to order FFA:
- To assess severity of retinal ischaemia (guides PRP decision in DR)
- To identify CNV in suspected wet ARMD
- To guide focal/grid laser treatment for DMO
- To identify cause of unexplained macular oedema
- Uses ICG dye (near-infrared fluorescence) → penetrates RPE better than fluorescein → visualises choroidal vasculature.
- Useful for: polypoidal choroidal vasculopathy (PCV — particularly common in Asian populations), occult CNV in ARMD, central serous chorioretinopathy.
- Non-invasive imaging of lipofuscin in the RPE.
- Hyper-autofluorescence = stressed/dying RPE cells accumulating lipofuscin → indicates areas at risk of progression (ARMD, RP).
- Hypo-autofluorescence = absent RPE = geographic atrophy (advanced dry ARMD).
- Used for monitoring geographic atrophy progression and HCQ retinal toxicity screening.
- When fundoscopy is not possible (dense cataract, vitreous haemorrhage obscuring view).
- Detects: retinal detachment, vitreous haemorrhage, intraocular tumours, posterior vitreous detachment.
- Essential before cataract surgery in eyes where the posterior segment cannot be visualised — you need to know what is behind the cataract.
| Test | What It Measures | Clinical Use |
|---|---|---|
| Electroretinogram (ERG) | Global retinal photoreceptor function (rods and cones separately under scotopic/photopic conditions) | Retinitis pigmentosa: severely reduced or extinguished scotopic (rod) ERG. Also used in unexplained vision loss, paediatric assessment |
| Visual evoked potential (VEP) | Optic nerve conduction time (from retina to visual cortex) | Optic neuritis / MS: delayed P100 latency [16]. Detects subclinical optic nerve demyelination. Also useful for malingering/non-organic vision loss. |
| Electrooculogram (EOG) | RPE function (Arden ratio: light peak / dark trough) | Best disease (vitelliform macular dystrophy): abnormal Arden ratio |
| Modality | Indication | Key Findings |
|---|---|---|
| MRI brain and orbits with contrast | Compressive optic neuropathy, pituitary tumour, optic neuritis, MS | Pituitary macroadenoma: sellar/suprasellar mass compressing chiasm [5]; Graves' orbitopathy: tendon-sparing EOM enlargement, apical crowding [17]; MS: periventricular and juxtacortical T2/FLAIR lesions [16] |
| CT orbits | Graves' orbitopathy (if MRI unavailable), orbital fractures, calcification (craniopharyngioma) | Characteristic tendon-sparing EOM enlargement; apical crowding indicates risk of ON compression [17] |
| CT brain | Acute presentations — to rule out haemorrhage, calcified lesions | Less sensitive than MRI for soft tissue detail |
Radiological assessment for Graves' ophthalmopathy: MRI orbit (more preferable) or plain CT orbit — crowding of the orbital apices, soft tissue changes, enlargement of extraocular muscles, optic nerve. [17]
These are ordered based on the suspected underlying cause:
| Suspected Cause | Blood Tests |
|---|---|
| DR | HbA1c, fasting glucose, lipid profile, RFT (diabetic nephropathy), UACR |
| GCA | ESR ( > 50 mm/h), CRP (markedly ↑), FBC (NcNc anaemia, thrombocytosis), ALP (often ↑) [15] |
| Pituitary tumour | Pituitary hormone panel: prolactin, IGF-1, cortisol (am), TFT, FSH/LH, testosterone/oestradiol |
| Toxic optic neuropathy | B12, folate, serum drug levels if applicable; methanol: ABG, RFT, Cl, EtOH, lactate, osmolality, OG/AG [12] |
| MS | CSF: oligoclonal IgG bands [16]; serum: AQP4-IgG (NMOSD), MOG-IgG |
- Gold standard for GCA diagnosis.
-
Must order urgently ( < 24–48 hours) or else risk permanent visual impairment. May be falsely negative due to patchy inflammation (skip lesions). [15]
- Histology: subacute granulomatous inflammation with giant cells, fragmentation of internal elastic lamina.
- Do NOT delay steroids while waiting for biopsy — biopsy remains positive for up to 2 weeks after starting prednisolone.
| Condition | History Clues | Bedside Signs | Key Investigation | Diagnostic Confirmation |
|---|---|---|---|---|
| Cataract | Glare, myopic shift, painless blur | ↓Red reflex, VA improves with pinhole, no RAPD | Slit-lamp biomicroscopy | Clinical (slit-lamp) |
| POAG / NTG | Insidious peripheral VF loss, FHx | Disc cupping, RNFL defects, ± ↑IOP | OCT RNFL, Humphrey VF, gonioscopy, IOP [13] | Disc + VF + ± IOP |
| PACG (chronic) | Haloes, dull ache, hyperopic | Shallow AC (van Herick), ↑IOP, disc cupping | Gonioscopy (closed angle), IOP | Gonioscopy + disc + VF |
| DR | DM history, often asymptomatic | Fundoscopy: dot-blot, exudates, NV | FFA (ischaemia extent), OCT macula (DMO) [4][14] | Dilated fundoscopy + ETDRS classification |
| ARMD (dry) | Age > 50, gradual central blur | Drusen, RPE changes | OCT macula, FAF | Fundoscopy + OCT |
| ARMD (wet) | Acute/subacute metamorphopsia | Subretinal fluid/haemorrhage, CNV | FFA/ICGA (CNV), OCT macula | FFA + OCT |
| RP | Night blindness, FHx, young adult | Bone-spicule pigment, arteriolar attenuation | ERG (extinguished scotopic) | ERG + genetic testing |
| Compressive ON | Bumping into things, headache | Bitemporal hemianopia, optic pallor | MRI brain with contrast [5] | MRI + VF |
| Graves' ON | Graves' disease, diplopia, proptosis | Proptosis, RAPD, ↓colour vision | MRI/CT orbits: tendon-sparing EOM enlargement, apical crowding [17] | Imaging + TFT + CAS |
| Toxic ON | Drug hx (ethambutol, methanol) | Bilateral central scotoma, ↓colour vision | VA/colour vision monitoring, VEP | Clinical + drug exposure |
| GCA | Age ≥ 50, headache, jaw claudication | Thickened tender temporal artery | ESR, CRP, temporal artery biopsy [15] | ACR criteria (≥ 3/5) |
Example 1: 68-year-old man with DM × 20 years. VA 6/24 bilaterally. No improvement with pinhole. RAPD negative. Red reflex normal. Fundoscopy: dot-blot haemorrhages in all 4 quadrants, venous beading in 2 quadrants, hard exudates near macula.
- Interpretation: Severe NPDR (meets 4-2-1 rule: haemorrhages in 4 quadrants + venous beading in ≥ 2 quadrants) [14] with probable DMO (hard exudates near macula, VA reduced). Next: OCT macula (confirm macular thickening), FFA (extent of ischaemia).
Example 2: 73-year-old woman. VA 6/12 OD, 6/60 OS. RAPD positive OS. Red reflex normal. Fundoscopy: C:D ratio 0.8 OS, 0.5 OD. IOP 16 mmHg bilaterally.
- Interpretation: Asymmetric optic disc cupping with RAPD and normal IOP → suspect NTG (left worse than right). IOP is "normal" but damage is progressing. Next: OCT RNFL (expect thinning OS > OD), HVF 24-2 (expect arcuate scotoma OS), gonioscopy (confirm open angles), pachymetry (CCT may be thin → IOP underestimated).
Example 3: 60-year-old woman with Graves' disease. Gradual ↓VA OS, difficulty with red-green colours. Proptosis bilaterally. RAPD positive OS.
- Interpretation: Graves' compressive optic neuropathy. Disproportional dyschromatopsia relative to VA loss is characteristic of optic neuropathy. [1] Next: MRI orbits (apical crowding, tendon-sparing EOM enlargement) [17], TFT, CAS score.
High Yield Summary — Diagnostics for Chronic Visual Loss
- Bedside algorithm = front to back: VA → pinhole → red reflex → RAPD → fundoscopy → VF. This sequence alone localises pathology in most cases.
- Key investigations per condition: Cataract = slit-lamp; Glaucoma = IOP + gonioscopy + OCT RNFL + HVF; DR = dilated fundoscopy + OCT macula ± FFA; ARMD = OCT ± FFA/ICGA; Compressive ON = MRI brain; GCA = ESR/CRP + temporal artery biopsy.
- 4-2-1 rule defines severe NPDR (> 50% progress to PDR): 4 quadrants haemorrhages, 2 quadrants venous beading, 1 quadrant IRMA. [14]
- ISNT rule: Inferior ≥ Superior ≥ Nasal ≥ Temporal rim thickness in normal disc. Violation suggests glaucoma. [13]
- IOP alone does not diagnose or exclude glaucoma. Thin CCT underestimates IOP (pachymetry important for NTG workup).
- OCT is the most important ancillary test — confirms DMO, ARMD subretinal fluid, glaucomatous RNFL thinning, macular hole, epiretinal membrane.
- MRI is preferred over CT for pituitary and orbital lesions (better soft tissue contrast) [5][17]; CT is adequate for Graves' if MRI unavailable.
Active Recall - Diagnostics of Chronic Visual Loss
References
[1] Senior notes: Ryan Ho Opthalmology, pp. 43–44 (Approach to Gradual Visual Loss) [2] Lecture slides: GC 122. Chronic Visual Loss.pdf, p. 44 (Take home messages) [4] Senior notes: Ryan Ho Endocrine, pp. 95–96 (Diabetic Retinopathy classification and pathophysiology) [5] Senior notes: Block A - I keep on bumping into people on my side: pituitary tumours; hypopituitarism.pdf, p. 1 [12] Senior notes: Ryan Ho Chemical Path, p. 41 (Methanol toxicity and diagnosis) [13] AOS material: AOS - Ophthalmology Annotated.pdf, p. 8 (Glaucoma cupping, ISNT rule, OCT, VF) [14] Senior notes: Ryan Ho Opthalmology, p. 69 (ETDRS classification of DR); Ryan Ho Endocrine, p. 96 (DR classification and CSME) [15] Senior notes: Ryan Ho Neurology, p. 65 (GCA diagnostic criteria and management) [16] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), p. 1277 (McDonald criteria, VEP, OCBs) [17] Senior notes: Block A - I am losing weight and sweating all the time: thyrotoxicosis; hypothyroidism.pdf, p. 28; Ryan Ho Endocrine, pp. 26–27 (Graves' ophthalmopathy imaging)
Management Algorithm and Treatment Modalities for Chronic Visual Loss
The management of chronic visual loss is cause-directed — there is no single treatment for "chronic visual loss" itself. The management framework can be divided into three pillars:
- Treat the underlying cause (e.g. cataract surgery, IOP-lowering for glaucoma, anti-VEGF for wet ARMD/DMO).
- Control systemic risk factors that drive or worsen the underlying eye disease (e.g. glycaemic control and BP control for DR, smoking cessation for ARMD and glaucoma).
- Rehabilitate and support the patient when vision loss is irreversible (visual aids, blind registration, psychosocial support).
3. Condition-Specific Management
Q3. How would you manage this patient? → Cataract surgery. Q4. What are the different options of surgery and their indications? → Old: ECCE. Modern: Phacoemulsification. [3]
3.1.1 Indications for Surgery
Cataract surgery is indicated when the cataract causes functional visual impairment that affects the patient's quality of life or daily activities. There is no absolute VA threshold — it depends on the patient's visual demands (a bus driver needs better VA than a retired sedentary patient). Other indications include:
- Cataract preventing adequate fundoscopic examination or treatment of posterior segment disease (e.g. DM patient needing laser for DR but cataract obscures the view)
- Lens-induced complications: phacomorphic glaucoma (swollen lens pushes iris forward → angle closure), phacolytic glaucoma (lens proteins leak through intact capsule → macrophage-mediated trabecular blockage)
3.1.2 Surgical Options
| Technique | Description | Status |
|---|---|---|
| Phacoemulsification ("phaco") | Ultrasonic probe fragments and aspirates the lens through a small (~2.2–2.8 mm) self-sealing incision. Foldable intraocular lens (IOL) inserted through the same incision. | Modern gold standard [3]. Small incision → rapid recovery, minimal astigmatism, same-day procedure |
| Extracapsular cataract extraction (ECCE) | Lens nucleus expressed through a larger (~10 mm) incision. Cortex aspirated. Rigid IOL inserted. | Older technique [3]. Still used when nucleus is too hard/dense for phaco (very mature cataracts), or in settings without phaco equipment |
| Intracapsular cataract extraction (ICCE) | Entire lens including capsule removed | Largely historical. No capsular bag to support IOL → anterior chamber IOL required. Higher complication rate |
| Femtosecond laser-assisted cataract surgery (FLACS) | Laser performs capsulotomy and lens fragmentation before phaco | Premium option; no clear superiority over standard phaco in most studies |
3.1.3 IOL Selection
- Monofocal IOL: Corrects for one focal distance (usually distance). Patient needs reading glasses. Most common.
- Multifocal / extended depth of focus (EDOF) IOL: Reduces spectacle dependence for near and distance. But can cause haloes, glare, reduced contrast sensitivity.
- Toric IOL: Corrects pre-existing astigmatism.
3.1.4 Complications of Cataract Surgery
| Timing | Complication | Mechanism |
|---|---|---|
| Intraoperative | Posterior capsule rupture ± vitreous loss | Technical difficulty; risk factors include mature cataract, small pupil, zonular weakness |
| Early postoperative | Endophthalmitis (0.03–0.1%) | Bacterial infection (most commonly S. epidermidis). Presents with pain, ↓VA, hypopyon within days. Ophthalmic emergency — requires intravitreal antibiotics ± vitrectomy |
| Early postoperative | Raised IOP | Retained viscoelastic, inflammation |
| Late postoperative | Posterior capsule opacification (PCO) | Residual lens epithelial cells proliferate on posterior capsule → "secondary cataract." Treated with YAG laser capsulotomy (simple outpatient procedure). Most common long-term complication (~20%) |
| Late postoperative | Cystoid macular oedema (Irvine-Gass syndrome) | Post-surgical inflammation → breakdown of blood-retinal barrier → macular oedema |
| Late postoperative | Retinal detachment | Vitreous changes post-surgery; higher risk in high myopes |
3.1.5 Contraindications / Cautions
- No absolute contraindications if visual rehabilitation is the goal.
- Relative: active intraocular inflammation (uveitis should be controlled for ≥ 3 months first), uncontrolled glaucoma (may need combined phaco + glaucoma surgery), retinal pathology that limits visual potential (counsel patient about realistic expectations).
The overarching principle: the only proven treatment for glaucoma is lowering IOP — even in normal-tension glaucoma, further IOP reduction slows progression. The target IOP depends on the stage of disease and the patient's baseline IOP.
Stepwise approach:
3.2.1 Medical Therapy — Topical IOP-Lowering Drops
| Drug Class | Mechanism | Examples | Key Side Effects |
|---|---|---|---|
| Prostaglandin analogues (PGA) | ↑Uveoscleral outflow (PGAs bind prostaglandin FP receptors on ciliary muscle → remodel extracellular matrix → ↑aqueous drainage through the alternative uveoscleral pathway) | Latanoprost, travoprost, bimatoprost, tafluprost | First-line for POAG/NTG. S/E: iris/periocular skin hyperpigmentation (irreversible in some), eyelash growth, periorbital fat atrophy ("sunken eyes"), mild conjunctival hyperaemia. C/I: active uveitis (may worsen inflammation), CMO risk |
| β-blockers | ↓Aqueous production (block β2-receptors on ciliary epithelium → ↓cAMP → ↓aqueous secretion) | Timolol, betaxolol | Systemic absorption → bradycardia, bronchospasm, fatigue, depression. C/I: asthma, COPD, heart block, severe bradycardia. Betaxolol (β1-selective) is somewhat safer for airways but less effective at IOP lowering |
| α2-agonists | ↓Aqueous production + ↑uveoscleral outflow | Brimonidine, apraclonidine | Allergy (30% with brimonidine — follicular conjunctivitis), fatigue, dry mouth. C/I: children < 2 years (CNS depression) |
| Carbonic anhydrase inhibitors (CAI) | ↓Aqueous production (inhibit CA II in ciliary epithelium → ↓bicarbonate and fluid secretion into posterior chamber) | Topical: dorzolamide, brinzolamide. Oral: acetazolamide | Topical: stinging, metallic taste. Oral: paraesthesia, malaise, renal stones, metabolic acidosis, hypoK, aplastic anaemia (rare). Oral CAI C/I: sulfonamide allergy |
| Cholinergic agonists (miotics) | ↑Trabecular outflow (contract ciliary muscle → opens trabecular meshwork) | Pilocarpine | Miosis (dim vision, especially at night), brow ache, accommodative spasm, myopic shift, retinal detachment risk. Rarely used for chronic POAG now but important for acute angle closure crisis |
| ROCK inhibitors (newer) | ↓Aqueous production + ↑trabecular outflow (inhibit Rho-associated kinase → relax trabecular meshwork cells) | Ripasudil, netarsudil | Conjunctival hyperaemia, cornea verticillata |
Topical β-Blocker — A Classic Exam Trap
Timolol eye drops cause systemic side effects because the drug is absorbed through the nasolacrimal duct mucosa and enters the systemic circulation bypassing first-pass metabolism. Always check for asthma, COPD, bradycardia, and heart block before prescribing. Teach patients punctal occlusion (press on the inner corner of the eye for 1–2 minutes after instilling drops) to reduce systemic absorption.
3.2.2 Laser Therapy
| Procedure | Indication | Mechanism |
|---|---|---|
| Selective Laser Trabeculoplasty (SLT) | POAG / NTG — as adjunct or sometimes first-line (LiGHT trial showed SLT can be initial therapy) | Low-energy laser selectively targets melanin-containing trabecular meshwork cells → triggers biological remodelling → ↑outflow. Repeatable. |
| Laser Peripheral Iridotomy (PI) | PACG — prophylactic and therapeutic | Laser creates a full-thickness hole in the peripheral iris → bypasses the pupillary block → allows aqueous to flow freely from posterior to anterior chamber → iris falls back → angle opens |
| Laser Cyclophotocoagulation | Refractory glaucoma | Destroys ciliary epithelium → ↓aqueous production. Reserved for advanced/refractory disease because it carries risk of phthisis (shrunken, non-functional eye) |
3.2.3 Surgical Therapy
| Procedure | Mechanism | Indications |
|---|---|---|
| Trabeculectomy | Creates a fistula from anterior chamber to subconjunctival space → aqueous drains under conjunctiva forming a "bleb" → absorbed by surrounding tissue | Failed medical/laser therapy, advanced glaucoma needing very low target IOP. Gold standard filtration surgery. Complications: bleb leak, bleb infection (blebitis/endophthalmitis), hypotony, choroidal detachment, cataract acceleration |
| Tube shunt (Ahmed, Baerveldt) | Silicone tube drains aqueous from AC to a plate in the equatorial subconjunctival space | Failed trabeculectomy, neovascular glaucoma, uveitic glaucoma |
| Minimally invasive glaucoma surgery (MIGS) | Various micro-devices (iStent, Hydrus, XEN gel stent) placed ab interno to enhance trabecular or subconjunctival outflow | Mild-moderate POAG, often combined with phaco. Lower complication profile but more modest IOP reduction than trabeculectomy |
| Lens extraction | Removing the (usually thickened) crystalline lens deepens the anterior chamber → opens the angle | Chronic PACG — phacoemulsification can be both the angle-opening procedure and the cataract treatment (EAGLE study showed lens extraction superior to laser PI for controlling IOP in PACG patients with cataract) |
3.2.4 Monitoring
- IOP, VF (HVF 24-2), and OCT RNFL every 6–12 months.
- Assess compliance — poor compliance is a major cause of treatment failure.
Treatment aims: Good BP control (target ≤ 140/90 mmHg), Good glycaemic control (target HbA1c ≤ 7%), Good lipid control. [18]
3.3.1 Systemic Risk Factor Control (All Stages)
Glycaemic control: HbA1c ≤ 7%. [4][18] This is the single most important intervention to prevent DR development and slow progression. The DCCT (T1DM) and UKPDS (T2DM) trials both showed that intensive glycaemic control reduces risk of DR development and progression by 50–75%.
| Risk Factor | Target | Preferred Agents |
|---|---|---|
| Glycaemia | HbA1c < 7% [18][19] | SGLT2 inhibitors, GLP-1 receptor agonists (also provide cardiovascular and renal benefits) |
| Blood pressure | ≤ 140/90 (some guidelines target ≤ 130/80 in DM) | ACEI / ARB (additional renal benefit) |
| Lipids | LDL < 1.8 mmol/L (if high CVD risk) | Statins; fenofibrate has some evidence for reducing DR progression |
| Smoking | Cessation | Counselling, NRT |
Rapid Glycaemic Control Can Paradoxically Worsen DR
Rapid implementation of tight glycaemic control is a risk factor for early worsening of diabetic retinopathy [4]. The mechanism is thought to be that chronically high glucose has led to compensatory upregulation of growth factors; when glucose drops rapidly, there is a transient mismatch that exacerbates ischaemia. Therefore, in patients with pre-existing moderate-severe NPDR, tighten glycaemic control gradually and monitor the retina closely.
3.3.2 Stage-Specific Ocular Treatment
Treatment of NPDR: Mild and moderate NPDR without macular oedema — NOT treated unless accompanied by CSME. Severe and very severe NPDR without macular oedema — can be treated with photocoagulation to reduce risk of progression to PDR. [18]
| Stage | Treatment | Rationale |
|---|---|---|
| Mild NPDR | Glycaemic control (HbA1c ≤ 7%). Monitor [4] | Only microaneurysms; low risk of progression (5% → PDR) |
| Moderate NPDR | Glycaemic control. Monitor [4] | Not enough ischaemia to warrant laser yet |
| Severe NPDR | Pan-retinal laser photocoagulation (PRP) [4][18] | > 50% risk of progression to PDR; PRP destroys ischaemic retina → ↓VEGF drive → ↓neovascularisation |
| PDR | PRP (primary treatment) ± intravitreal anti-VEGF ± vitrectomy [18] | PRP halts NV. Anti-VEGF causes rapid regression of NV (adjunctive). Vitrectomy for vitreous haemorrhage or tractional RD |
| DMO (at any stage) | Intravitreal anti-VEGF (1st line: ranibizumab, aflibercept, bevacizumab) ± intravitreal steroid (triamcinolone, dexamethasone implant/Ozurdex) ± focal/grid laser [4][18] | Anti-VEGF reduces vascular permeability → ↓macular oedema → ↑VA |
3.3.3 Pan-Retinal Photocoagulation (PRP) — In Detail
- Mechanism: Argon laser burns are applied to the peripheral retina (deliberately sparing the macula and optic disc) → destroys ischaemic retina → ↓total retinal oxygen demand → ↓VEGF production → neovessels regress.
- Why destroy peripheral retina? Think of it as triage — you sacrifice peripheral (low-acuity) retina to save the macula (high-acuity central vision). By reducing the metabolic demand of the dying periphery, you redirect oxygen to the macula and remove the stimulus for VEGF-driven neovascularisation.
Complications of PRP: pain during treatment, loss of dark adaptation (poor night vision), visual field loss, visual acuity loss. [18]
- These are all logical consequences: burning peripheral retina → fewer functioning rods → worse night vision and smaller VF. Some central VA loss occurs from scattered light during treatment or inadvertent macular damage.
Patients with PDR and CSME should receive PRP for treatment of PDR first and subsequently receive anti-VEGF for CSME. [18]
3.3.4 Intravitreal Anti-VEGF — In Detail
| Drug | Mechanism | Notes |
|---|---|---|
| Ranibizumab (Lucentis) | Monoclonal antibody fragment binding VEGF-A | Designed specifically for intraocular use (small molecule penetrates retina well) |
| Aflibercept (Eylea) | Fusion protein acting as VEGF "trap" — binds VEGF-A, VEGF-B, and PlGF | Longer duration of action → can be given Q8 weeks after loading |
| Bevacizumab (Avastin) | Full-length monoclonal antibody against VEGF-A | Off-label but widely used due to much lower cost (same molecule family as ranibizumab) |
| Brolucizumab (Beovu) | Single-chain antibody fragment | Higher risk of intraocular inflammation; used with caution |
| Faricimab (Vabysmo) | Bispecific antibody targeting VEGF-A AND angiopoietin-2 | Newest agent; can extend treatment intervals up to Q16 weeks |
- Regimen: Typically a loading phase of 3 monthly injections followed by PRN (as needed) or treat-and-extend regimen based on OCT response. [1]
- Side effects: Endophthalmitis (< 0.05% per injection), raised IOP (transient), retinal detachment (very rare), vitreous haemorrhage.
- Antiplatelet and anticoagulation drugs can be continued safely [18] — this is a common exam question. The intraocular injection does not cause significant enough bleeding to warrant stopping antithrombotic therapy.
3.3.5 Vitrectomy
Vitrectomy — removal of media opacities and to relieve vitreous traction. Indications: vitreous haemorrhage, retinal detachment, neovascularization of iris (rubeosis iridis), refractory to photocoagulation. [18]
3.4.1 Dry ARMD
No proven effective treatment for dry AMD. Daily oral supplements if extensive drusen/atrophy → AREDS2 formulation (vitamin C, E, lutein, zeaxanthin, zinc, copper). Standard AREDS formulation for non-smokers contains β-carotene which may ↑risk of lung cancer in smokers → use AREDS2 formulation without β-carotene for smokers. RF management: quit smoking. Self-monitoring using Amsler grid. Patient education: early follow-up if develop central scotoma, metamorphopsia and blurring. [1]
Why AREDS2 supplements? The theory is that oxidative damage contributes to RPE and photoreceptor death. Antioxidants (vitamins C/E) and macular carotenoids (lutein, zeaxanthin — which are normally concentrated in the macula and filter harmful blue light) may slow this process. AREDS2 trial showed ~25% risk reduction of progression from intermediate to advanced AMD over 5 years.
3.4.2 Wet ARMD
Intravitreal VEGF inhibitor (gold standard). Examples: bevacizumab (Lucentis), ranibizumab (Avastin), aflibercept (Eylea), conbercept. Regimen: loading (3× Q1 monthly injections) + PRN injections depending on VA, central retinal thickness (OCT), presence of subretinal fluid and changes in clinical signs. [1]
Note: The source text has a naming swap — bevacizumab = Avastin, ranibizumab = Lucentis. This is a commonly confused point.
| Agent | Brand Name |
|---|---|
| Bevacizumab | Avastin (off-label, cheaper) |
| Ranibizumab | Lucentis |
| Aflibercept | Eylea |
Photodynamic therapy (PDT): use of photosensitizing agents (e.g. verteporfin) that pool in neovascular membranes and subsequently amass ROS upon infrared activation. [1] PDT is used mainly for polypoidal choroidal vasculopathy (PCV) — a variant of wet ARMD that is more common in Asian (including Chinese) populations. In HK, PCV may account for 20–50% of wet ARMD cases, and combination anti-VEGF + PDT is often the preferred treatment.
Treatment is often suboptimal — majority will lose central vision despite treatment. Offer visual aids (magnifiers, telescopes, CCTV). Ensure good social and family support with adaptation to ADL. Consider blind registration and disability allowances. [1]
Prevention: ↓risk by healthy lifestyle — ↑fruit, green vegetables, fish and nut intake; physical exercise; ↓sunlight exposure; quit smoking. [1]
Indications for surgery for pituitary tumour: all tumours causing pituitary hyperfunction, all macroadenomas ( > 1 cm), vision loss/visual field deficits, mass effect (headaches or causing hypopituitarism), pituitary apoplexy (emergency). [5]
Surgical approach: Transphenoidal (route of choice — transnasal endoscopic or sub-labial); Transfrontal for very large suprasellar extension or severe chiasmal compression. [5]
One pituitary tumour that despite being hyperfunctional is preferably treated medically = Prolactinoma (dopamine agonists: cabergoline, bromocriptine). [5]
Complications of surgery: residual/recurrence (especially macroadenomas), iatrogenic hypopituitarism/diabetes insipidus, postoperative bleeding, CSF rhinorrhoea → requires antibiotics to prevent ascending meningitis. [5]
Why does surgery restore vision? Removing the tumour mass relieves pressure on the optic chiasm → axonal compression is reversed → visual field can improve dramatically, especially if the compression was of short duration. Long-standing compression causes irreversible axonal loss → optic atrophy → poor recovery.
Significant/active GO → do not use RAI as definitive therapy (risk of exacerbation). May consider total thyroidectomy. [6]
Management of Graves' orbitopathy with compressive optic neuropathy is a medical emergency:
- IV methylprednisolone pulses (500 mg–1 g daily for 3 days, then taper) — to rapidly reduce orbital inflammation and decompression.
- Orbital decompression surgery — if vision does not improve with steroids, or if disease is inactive but fibrotic muscles are still causing compression. Involves removing bone from the orbital walls to create more space.
- Definitive thyroid treatment: Total thyroidectomy preferred over RAI for patients with significant GO — because RAI can worsen ophthalmopathy by releasing thyroid antigens and boosting TRAb levels. [6]
- Steroid-sparing agents: Mycophenolate, azathioprine; teprotumumab (anti-IGF-1R monoclonal antibody) is a newer agent showing dramatic improvement in proptosis and diplopia.
Urgent prednisolone 60 mg daily. Urgent treatment prevents blindness and brainstem stroke and ↓headache. Parenteral high dose if complications already occurred. Gradual ↓dosage to maintenance level according to ESR level. [15]
| Scenario | Treatment |
|---|---|
| GCA without visual loss | Prednisolone 40–60 mg/day PO; taper over 12–24 months guided by ESR/CRP |
| GCA WITH visual symptoms (AION, amaurosis fugax) | IV methylprednisolone 500 mg–1 g/day for 3 days → then oral prednisolone taper |
| Steroid-sparing | Tocilizumab (anti-IL-6R) — now first-line steroid-sparing agent (GiACTA trial); methotrexate as alternative |
| All patients | Low-dose aspirin (may reduce risk of visual loss); PPI for gastric protection; calcium + vitamin D + bisphosphonate for steroid-induced osteoporosis prevention |
Must order temporal artery biopsy urgently ( < 24–48 hours) — but do NOT delay steroids while waiting. [15]
Ethambutol: generally reversible with withdrawal. Indication for ethambutol: ↑risk of isoniazid resistance. Relative contraindications: inability to report symptoms, lack reasonable vision to carry out ADL, renal insufficiency (2/3 of E is renally excreted → ↑risk of overdose). Monitoring: baseline VA + self-reporting ± Q1 monthly VA if > 15–20 mg/kg/day, taking > 2 months, CKD. [20]
- Key management: Stop the offending drug immediately and monitor for recovery.
- For methanol: ABG, RFT, osmolality, OG/AG → fomepizole (1st-line) or IV ethanol (competitive ADH inhibitor to prevent formate formation) + haemodialysis if severe (metabolic acidosis, visual symptoms, methanol level > 50 mg/dL). [12]
- No curative treatment available.
- Supportive: visual aids (magnifiers, filters to reduce glare), orientation and mobility training, genetic counselling, psychosocial support.
- Emerging therapies: gene therapy (e.g. voretigene neparvovec/Luxturna for RPE65-related retinal dystrophy — the first FDA/EMA-approved gene therapy for an inherited retinal disease), retinal prosthesis ("bionic eye"), stem cell therapy (research stage).
- Vitamin A palmitate (15,000 IU/day) may modestly slow ERG decline (Berson et al.), but evidence is controversial and monitoring for hepatotoxicity is needed. Not widely recommended in current practice.
- Avoid excessive vitamin E (may accelerate cone loss — Berson trial).
Eye check before treatment and Q1 yearly after 5 years for HCQ use. [21]
- Dose: Keep HCQ < 5 mg/kg actual body weight/day (updated from older < 6.5 mg/kg recommendation) to minimize risk.
- Screening: Baseline ophthalmological assessment → annual screening from year 5 of use (or from year 1 if high risk: renal impairment, high dose, pre-existing macular disease, concomitant tamoxifen).
- Screening modality: OCT macula (ganglion cell analysis) + Humphrey VF 10-2 ± fundus autofluorescence. Look for parafoveal thinning (earliest sign on OCT) or paracentral scotoma on VF.
- If toxicity detected: Stop HCQ immediately. Damage may continue to progress even after cessation ("window of toxicity") but is less severe if caught early.
When vision loss cannot be reversed (end-stage glaucoma, geographic atrophy, advanced RP), the focus shifts to:
| Intervention | Purpose |
|---|---|
| Low vision aids | Magnifiers (handheld, stand, electronic/CCTV), telescopes (for distance), prisms, large-print materials |
| Environmental modification | High-contrast markings, good lighting, tactile markers |
| Orientation and mobility training | White cane use, guide dog |
| Technology | Screen readers, voice assistants, smartphone accessibility features |
| Psychosocial support | Counselling (depression is common — up to 30% in severe visual loss), support groups |
| Blind registration | Eligibility for disability allowances and social services in HK |
| Driving assessment | Legal requirement — must meet VF and VA standards for driving (HK: ≥ 6/12 binocular, adequate VF) |
| Condition | 1st-Line Treatment | 2nd-Line / Adjunctive | Key Contraindications / Cautions |
|---|---|---|---|
| Cataract | Phacoemulsification + IOL [3] | ECCE if very dense nucleus | Active uveitis (control first); counsel about posterior segment co-pathology |
| POAG / NTG | PGA drops (latanoprost) | Add β-blocker, CAI, α-agonist → SLT → Trabeculectomy / MIGS | β-blocker: asthma, COPD, heart block. CAI: sulfonamide allergy |
| Chronic PACG | Laser PI ± IOP-lowering drops | Lens extraction (phaco); Trabeculectomy | — |
| Mild-Mod NPDR | Glycaemic + BP + lipid control [4][18] | — | Avoid rapid glycaemic correction in severe NPDR |
| Severe NPDR / PDR | PRP [4][18] | Anti-VEGF (adjunctive), vitrectomy (VH/TRD) | PRP: warn about ↓night vision, ↓VF |
| DMO | Intravitreal anti-VEGF [4][18] | Intravitreal steroid (Ozurdex), focal/grid laser | Steroid: ↑IOP, cataract acceleration; laser: risk of paracentral scotoma |
| Dry ARMD | AREDS2 supplements + RF modification [1] | — | β-carotene formulation: C/I in smokers (↑lung cancer risk) |
| Wet ARMD | Intravitreal anti-VEGF [1] | PDT (especially for PCV in Asians) | Endophthalmitis risk per injection |
| Pituitary compression | Transphenoidal surgery [5] | Transfrontal if large suprasellar extension; dopamine agonist for prolactinoma | Surgical complications: hypopituitarism, DI, CSF leak |
| Graves' ON | IV methylprednisolone → orbital decompression | Teprotumumab; total thyroidectomy | Avoid RAI if significant GO [6] |
| GCA | Prednisolone 60 mg/day (IV methyl-pred if visual Sx) [15] | Tocilizumab (steroid-sparing) | Long-term steroid S/E: osteoporosis, DM, infection |
| Ethambutol ON | Stop ethambutol [20] | Monitor for recovery (usually reversible) | — |
| RP | Supportive + visual rehabilitation | Gene therapy (if RPE65 mutation) | No proven pharmacological cure |
High Yield Summary — Management of Chronic Visual Loss
- Phacoemulsification is the modern gold standard for cataract surgery [3]. Most common complication long-term = posterior capsule opacification (treated by YAG laser capsulotomy).
- Glaucoma: Only proven treatment = IOP lowering. PGA drops 1st-line. β-blockers C/I in asthma/COPD/heart block. SLT is an alternative 1st-line. Trabeculectomy for refractory cases. Lens extraction increasingly used for chronic PACG.
- DR management is stage-dependent: Mild/moderate NPDR = systemic control + monitor. Severe NPDR/PDR = PRP. DMO = intravitreal anti-VEGF (1st-line). PRP complications: ↓night vision, ↓VF, pain. [18]
- Dry ARMD: no cure — AREDS2 supplements + RF modification. Wet ARMD: intravitreal anti-VEGF 1st-line [1]. PDT for PCV (common in Asians).
- GCA: DO NOT DELAY steroids. Prednisolone 60 mg/day (or IV methylprednisolone if visual symptoms). [15] Tocilizumab for steroid-sparing.
- Pituitary tumour with visual field deficits → transphenoidal surgery. Exception: prolactinoma → medical therapy with dopamine agonist first. [5]
- Anti-VEGF agents do NOT require stopping antiplatelets/anticoagulants. [18]
- HCQ: annual retinal screening from year 5; keep dose < 5 mg/kg/day. [21]
Active Recall - Management of Chronic Visual Loss
References
[1] Senior notes: Ryan Ho Opthalmology, pp. 44, 62 (Approach to Gradual Visual Loss; ARMD management) [2] Lecture slides: GC 122. Chronic Visual Loss.pdf, p. 44 (Take home messages) [3] AOS material: AOS - Ophthalmology.pdf, p. 3; AOS - Ophthalmology Annotated.pdf, p. 3 (Cataract PBL — phacoemulsification vs ECCE) [4] Senior notes: Ryan Ho Endocrine, pp. 96–97 (DR classification and treatment; DMO treatment) [5] Senior notes: Block A - I keep on bumping into people on my side: pituitary tumours; hypopituitarism.pdf, p. 11 (Indications for pituitary surgery, surgical approach, complications) [6] Senior notes: Ryan Ho Endocrine, pp. 26–27; Block A - I am losing weight and sweating all the time.pdf, p. 28 (Graves' ophthalmopathy management, RAI contraindication) [12] Senior notes: Ryan Ho Chemical Path, p. 41 (Methanol management) [15] Senior notes: Ryan Ho Neurology, p. 65 (GCA treatment — urgent prednisolone) [18] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), pp. 1518–1520 (DR/DMO treatment, PRP, anti-VEGF, vitrectomy indications) [19] Senior notes: Block A - Polyuria and polydipsia: glucose metabolism; DM; DKA.pdf, p. 18 (HbA1c target < 7%) [20] Senior notes: Ryan Ho Respiratory, p. 89 (Ethambutol ocular toxicity — indications, contraindications, monitoring) [21] Senior notes: Ryan Ho Rheumatology, p. 76 (HCQ monitoring — eye check before Tx and Q1 yearly after 5 years)
Complications of Chronic Visual Loss and Its Underlying Conditions
This section covers complications from two perspectives:
- Complications of the diseases that cause chronic visual loss — i.e. what happens if the underlying condition progresses or is left untreated (the ocular and systemic "downstream" damage).
- Complications of the treatments used for chronic visual loss — i.e. iatrogenic harm.
The key conceptual point: most causes of chronic visual loss are progressive and irreversible once advanced. Complications are largely the result of failure to diagnose early, failure to treat aggressively, or inadequate systemic risk factor control. Understanding these complications is what motivates the screening, monitoring, and staged-treatment approach discussed in previous sections.
If a cataract is left untreated beyond the point of visual disability, several complications can arise — not just from poor vision, but from the cataract itself becoming pathological:
| Complication | Mechanism | Clinical Consequence |
|---|---|---|
| Functional blindness | Progressive opacification → total light obstruction | ↓Independence, falls, depression. Leading cause of preventable blindness worldwide |
| Phacomorphic glaucoma | Intumescent (swollen) cataract → lens pushes iris forward → secondary acute angle closure | Eye pain, ↑IOP, corneal oedema → optic nerve damage. This is an acute complication of a chronic condition |
| Phacolytic glaucoma | Mature/hypermature lens → high-molecular-weight proteins leak through intact capsule → macrophage ingestion → macrophages clog trabecular meshwork | ↑IOP, pain, flare in AC. Must remove cataract to resolve |
| Phacoanaphylactic uveitis (lens-induced uveitis) | Lens capsule rupture (spontaneous or traumatic) → lens proteins exposed to immune system → granulomatous inflammation | Painful red eye, anterior uveitis |
| Lens subluxation/dislocation | Weakened zonules (e.g. pseudoexfoliation, Marfan syndrome, homocystinuria) → lens shifts → refractive instability or pupillary block | Variable VA, monocular diplopia, secondary glaucoma if dislocated into anterior chamber or vitreous |
Falls and Cataract
In elderly patients, untreated bilateral cataracts are a major risk factor for falls and hip fractures. Cataract surgery has been shown to reduce fall risk by ~34% (EPIC study). This is a frequently tested concept linking ophthalmology with geriatrics.
2. Complications of Glaucoma
| Complication | Mechanism | Key Points |
|---|---|---|
| Irreversible blindness | Progressive retinal ganglion cell death → complete loss of VF → no light perception | Glaucoma is the leading cause of irreversible blindness worldwide. Central vision is lost last, so patients are functionally blind (no navigational vision) even while they can still read (tunnel vision) — then central vision also goes |
| Falls and injury | Peripheral VF loss → inability to detect obstacles, steps, kerbs | Patients may not realise they have lost peripheral vision until they bump into things or have accidents |
| Treatment | Complication | Mechanism |
|---|---|---|
| Topical β-blockers | Bronchospasm, bradycardia, heart block, depression, fatigue | Systemic absorption through nasolacrimal mucosa → bypasses first-pass metabolism |
| Prostaglandin analogues | Iris hyperpigmentation (irreversible), periorbital fat atrophy, cystoid macular oedema (rare), uveitis flare | PGA-mediated melanocyte stimulation in iris; prostaglandin-induced inflammation |
| Topical CAIs | Stinging, metallic taste; oral CAIs → paraesthesia, malaise, renal stones, metabolic acidosis, blood dyscrasias | Carbonic anhydrase inhibition affects multiple organ systems |
| SLT / ALT | IOP spike (transient), mild anterior uveitis | Trabecular meshwork inflammation from laser energy |
| Trabeculectomy | Bleb leak, blebitis, endophthalmitis, hypotony (IOP too low), hypotony maculopathy, choroidal detachment, cataract acceleration, bleb dysesthesia | Filtering surgery creates a controlled fistula; if too much aqueous drains → hypotony; thin-walled bleb can leak or become infected |
| Tube shunts | Tube erosion through conjunctiva, corneal decompensation (tube touches endothelium), diplopia, hypertony if tube blocked, hypotony if valve malfunctions | Mechanical complications of an implanted device |
3. Complications of Diabetic Retinopathy
This is the highest-yield section because DM eye complications are examined from multiple angles (ophthalmology, endocrinology, medicine).
Important ocular complications of diabetes mellitus: (1) Diabetic retinopathy (non-proliferative vs proliferative), (2) Diabetic macular oedema, (3) Neovascular glaucoma (new vessels on iris and anterior chamber angle leading to high intraocular pressure and optic nerve degeneration), (4) CN III, IV, VI palsies, (5) Cataract (activation of pentose pathway, leads to accumulation of sorbitol within the lens). [22]
| Complication | Stage | Mechanism | Clinical Impact |
|---|---|---|---|
| Vitreous haemorrhage | PDR | Neovascularization with fragile vessels → rupture → blood enters vitreous [4] | Sudden painless loss of vision; may clear spontaneously (1%/day) or require vitrectomy |
| Tractional retinal detachment | PDR | Fibrosis of abnormal vessels → fibrovascular membranes contract → pull retina off the RPE [4] | Progressive VF loss; if macula detaches → severe irreversible central vision loss. Requires vitrectomy |
| Neovascular (rubeotic) glaucoma | PDR | Rubeosis iridis: VEGF acts on iris and angle → new vessels grow into drainage angle → fibrovascular membrane blocks aqueous outflow → ↑↑IOP [4][22] The concept is important: "the VEGF has nowhere to go and act on when the whole retina is ischaemic, moves anteriorly to the iris and messes things up there" [22] | Painful red eye, markedly elevated IOP, corneal oedema, rapidly progressive optic nerve damage. Very difficult to treat — requires urgent PRP + intravitreal anti-VEGF + glaucoma medications ± glaucoma surgery |
| Diabetic macular oedema (DMO) | Any stage | Breakdown of inner blood-retinal barrier → fluid leaks into macula → macular thickening | Commonest cause of vision loss in DM patients [4]. Gradual central blur |
| Cataract | Any duration | Accumulation of sorbitol within the lens [4][22] via the polyol (aldose reductase) pathway | Earlier onset and faster progression than age-related cataract |
| CN III, IV, VI palsies | Any duration | Diabetic mononeuritis multiplex: microangiopathy → ischaemic infarction of vasa nervorum of cranial nerves [22][4] | Diplopia, ptosis (CN III — typically pupil-sparing because pupillary fibres run on the outside of the nerve and receive collateral blood supply; ischaemic damage affects the inner core first). CN III palsy in DM is typically pupil-sparing; in compressive lesions (aneurysm) it is pupil-involving — classic exam discriminator |
| Fluctuating refractive errors | Poor glycaemic control | Osmotic changes in the lens: hyperglycaemia → sorbitol accumulation → lens swelling → myopic shift; hypoglycaemia reversal → hyperopic shift | Patients describe vision "changing day to day." Wait for glycaemic control to stabilise before prescribing glasses |
| ↑Eye infections | Any duration | Immunosuppression from hyperglycaemia → ↑susceptibility to bacterial/fungal infections | Post-surgical endophthalmitis risk is higher in DM patients |
The VEGF Cascade in DR Complications
Understanding VEGF as the central mediator links all the severe complications: retinal ischaemia → VEGF secretion → neovascularisation on the retina (vitreous haemorrhage, tractional RD) AND on the iris (rubeotic glaucoma) AND increased vascular permeability (macular oedema). This is why anti-VEGF is effective across multiple DR complications — it targets the root cause.
Classification of chronic diabetic complications — Microvascular (more A1c-dependent): Retinopathy (90%), Neuropathy (70–90%), Nephropathy (30–40%). Macrovascular (less A1c-dependent): IHD (accounts for 70% deaths in DM), Peripheral vascular disease, Cerebrovascular disease. [4][22][23]
The presence of diabetic retinopathy is a sentinel sign that other microvascular complications likely coexist or will develop:
- DR + nephropathy coexist in the vast majority of T1DM patients with overt nephropathy.
- Absence of retinopathy in a DM patient with renal impairment is a "red flag" for non-diabetic nephropathy [24] — because in typical DM nephropathy, retinopathy almost always precedes or accompanies nephropathy (they share the same microvascular pathophysiology). If the kidneys are failing but the retina looks normal, think about other causes of kidney disease.
Annual microvascular screen for all T2DM and T1DM ≥ 5 years from diagnosis (or ≥ 10 years or at puberty): involves foot examination (including monofilament test), UACR and dilated eye exam. [4][23]
| Treatment | Complication | Mechanism |
|---|---|---|
| PRP | Loss of dark adaptation (poor night vision), visual field loss, visual acuity loss, pain during treatment [18] | Laser deliberately destroys peripheral retina → ↓rod photoreceptors → ↓scotopic vision and ↓VF |
| Intravitreal anti-VEGF | Endophthalmitis (< 0.05%/injection), transient IOP spike, retinal detachment (rare), vitreous haemorrhage | Needle puncture introduces infection risk; VEGF inhibition may theoretically affect retinal vasculature |
| Intravitreal steroids | Steroid-induced glaucoma (↑IOP in ~30%), cataract acceleration | Steroid deposits in trabecular meshwork → ↑outflow resistance; steroid-mediated lens epithelial changes |
| Vitrectomy | Cataract (almost universal after vitrectomy in phakic patients), retinal detachment, endophthalmitis, vitreous haemorrhage, neovascular glaucoma | Removal of vitreous changes intraocular oxygen dynamics → lens exposed to more oxygen → accelerated oxidative damage → cataract |
| Complication | Type | Mechanism |
|---|---|---|
| Irreversible central vision loss | Both dry and wet | Geographic atrophy (dry) destroys foveal photoreceptors; disciform scar (wet) replaces foveal tissue with fibrous tissue |
| Conversion from dry to wet | Dry → Wet | ~15% of dry ARMD converts to wet ARMD over time. RPE dysfunction → VEGF upregulation → CNV development. This is why self-monitoring with Amsler grid is critical |
| Subretinal haemorrhage | Wet | CNV bleeds under the retina → sudden central vision loss; large haemorrhages are toxic to photoreceptors (iron-mediated oxidative damage) |
| Disciform scar | Wet (end-stage) | Repeated CNV → fibrosis → permanent macular scar → irreversible central scotoma |
| Charles Bonnet syndrome | Both (advanced) | Loss of visual input → visual cortex "fills in" with spontaneous activity → formed visual hallucinations (people, animals, patterns). Patient has insight (knows they are not real) — distinguishes from psychotic hallucinations |
| Depression and social isolation | Both | Loss of ability to read, recognise faces, drive → profound functional disability |
Sight-threatening complications include: (1) Compressive optic neuropathy ( < 5%): oversized recti + orbital fat → apical crowding → compressive optic neuropathy. Symptoms: slowly progressive ↓vision (esp colour vision, contrast sensitivity). Signs: optic disc oedema/pallor, RAPD+, central scotoma with inferior arcuate defects. Prognosis: usually stabilises over 3–5 years but can lead to blindness. (2) Exposure keratopathy: RFs — lagophthalmos, degree of proptosis, integrity of Bell's reflex. S/S: chemosis, punctate erosions, corneal ulcer, corneal perforation. (3) Secondary open-angle glaucoma due to ↑episcleral venous pressure and EOM swelling compressing onto the globe. [6]
| Complication | Mechanism | Why It Happens |
|---|---|---|
| Compressive optic neuropathy | Enlarged extraocular muscles (especially medial and inferior recti) and expanded orbital fat → apical crowding at the orbital apex → optic nerve compression | The orbit is a rigid bony cone. As soft tissue volume increases, the only "give" is forward (proptosis) or backward (compressing the optic nerve at the apex where it enters the optic canal) |
| Exposure keratopathy | Lagophthalmos (incomplete lid closure due to proptosis and lid retraction) → cornea exposed → desiccation → epithelial breakdown → corneal ulcer → perforation (worst case) | The cornea needs a complete tear film and lid coverage to stay healthy. Proptosis pushes the eye forward while retracted lids cannot cover it |
| Secondary open-angle glaucoma | ↑Episcleral venous pressure (from orbital congestion) + direct compression of globe by swollen EOMs → ↑IOP | When blood cannot drain from the eye easily (↑downstream venous pressure), aqueous also cannot drain effectively → IOP rises |
Complications of surgical treatment: residual/recurrence (especially for macroadenomas), iatrogenic hypopituitarism/diabetes insipidus, postoperative bleeding, CSF rhinorrhoea → will require antibiotics to prevent ascending meningitis. [5]
| Complication | Timing | Mechanism |
|---|---|---|
| Permanent visual field loss | If diagnosis delayed | Prolonged chiasmal compression → Wallerian degeneration of optic nerve fibres → irreversible |
| Hypopituitarism | Pre-op (from tumour compression) or post-op (from surgical damage) | Tumour compresses normal pituitary tissue → ↓hormone secretion; surgery may damage remaining functioning cells. Classical order of loss: GH → LH/FSH → TSH → ACTH (most resistant) |
| Diabetes insipidus (DI) | Post-op (transient in ~30%, permanent in ~2–5%) | Damage to posterior pituitary or pituitary stalk → ↓ADH → dilute polyuria |
| CSF rhinorrhoea | Post-op | Defect in sellar floor repair → CSF leaks through sphenoid sinus into nose. Risk of ascending meningitis |
| Pituitary apoplexy | Pre-op (emergency) | Haemorrhage or infarction within the tumour → sudden expansion → acute compression of chiasm, cavernous sinus (CN III, IV, VI), hypothalamus. Headache + visual loss + ophthalmoplegia ± altered consciousness |
| Agent | Complication if Not Recognised | Reversibility |
|---|---|---|
| Ethambutol | Progressive bilateral central scotoma → functional blindness | Generally reversible with withdrawal [20]. But if continued despite symptoms → irreversible optic atrophy |
| Methanol | Severe bilateral optic neuropathy → permanent blindness | Partially reversible if treated early (fomepizole + haemodialysis); often permanent if treatment delayed |
| HCQ/CQ (hydroxychloroquine) | Bull's eye maculopathy → progressive, irreversible ring scotoma → central vision loss | Irreversible once established — may even progress after drug cessation ("window of toxicity"). This is why screening is so important |
| Isoniazid | Optic neuritis (rare) → reversible with drug cessation ± pyridoxine | Usually reversible |
For patients with impaired kidney function, ethambutol can cause optic neuritis (2/3 of ethambutol is renally excreted → ↑risk of overdose). [25]
Ethambutol and Renal Function
Avoid ethambutol in patients with very poor renal function (on dialysis) [8] because 2/3 of ethambutol is renally excreted. Accumulation → ↑risk of optic neuritis at "standard" doses. If it must be used, dose-adjust and monitor VA and colour vision even more frequently.
| Complication | Mechanism | Frequency |
|---|---|---|
| Posterior subcapsular cataract | Chronic intraocular inflammation and oxidative stress in RP → lens epithelial changes | Up to 50% of RP patients |
| Cystoid macular oedema | Breakdown of blood-retinal barrier from chronic RPE/photoreceptor dysfunction | 10–20%; may respond to topical/oral CAIs |
| Epiretinal membrane | Chronic retinal surface gliosis | Common incidental finding |
| Complete blindness | Progressive loss of all remaining photoreceptors including central cones | Variable; most patients have VA < 6/60 by age 50. Some retain useful central vision into old age |
| Psychosocial impact | Young-onset progressive blindness → career limitations, relationship difficulties, depression | Major — genetic counselling and psychosocial support are essential |
Complications: retinal vascular disease (CRAO/BRAO, CRVO/BRVO, retinal arterial macroaneurysms), retinal ischaemia (neovascularisation → vitreous haemorrhage, RRD), epiretinal membrane, ↑progression of DM retinopathy, chronic papilloedema → optic nerve atrophy. [1]
Chronic hypertension damages retinal arterioles → arteriosclerotic changes → at arteriovenous crossings, the thickened arteriole compresses the underlying vein → this is the mechanism of branch retinal vein occlusion (BRVO) — one of the most common retinal vascular complications of hypertension.
These complications apply regardless of the underlying aetiology and are frequently overlooked:
| Complication | Mechanism | Relevance |
|---|---|---|
| Falls and fractures | ↓Visual input → impaired balance, obstacle detection, depth perception | 2–3× increased fall risk; hip fractures carry significant morbidity/mortality in elderly |
| Depression and anxiety | Loss of independence, social isolation, inability to read/drive/recognise faces | Prevalence of depression ~25–30% in visually impaired adults; often under-recognised and under-treated |
| Social isolation | Difficulty with communication (lip-reading), navigation, participation in activities | Contributes to cognitive decline and depression |
| Cognitive decline | Sensory deprivation hypothesis — reduced visual input → reduced cognitive stimulation → accelerated dementia | Associations between visual impairment and dementia are increasingly recognised; cataract surgery may reduce dementia risk |
| Loss of driving licence | Legal requirement for minimum VA and VF | Major impact on independence, employment, and quality of life |
| Charles Bonnet syndrome | Visual deafferentation → spontaneous visual cortex activity → formed hallucinations | Patient retains insight; important to reassure that this is NOT a psychiatric condition |
| Treatment | Target Condition | Key Complications |
|---|---|---|
| Phacoemulsification | Cataract | PCO (20%), endophthalmitis (0.03–0.1%), RD, CMO, IOL dislocation |
| Topical β-blockers | Glaucoma | Bronchospasm, bradycardia, depression |
| PGA drops | Glaucoma | Iris hyperpigmentation, periorbital fat atrophy, CMO, uveitis |
| Trabeculectomy | Glaucoma | Bleb infection, hypotony, cataract, choroidal detachment |
| PRP | PDR, severe NPDR | ↓Night vision, ↓VF, ↓VA, pain [18] |
| Intravitreal anti-VEGF | DMO, wet ARMD, PDR | Endophthalmitis, IOP spike, RD (all rare) |
| Intravitreal steroids | DMO, RVO macular oedema | Steroid glaucoma (↑IOP ~30%), cataract |
| Vitrectomy | VH, TRD, ERM | Cataract (near-universal in phakic eyes), RD, endophthalmitis |
| Transphenoidal surgery | Pituitary tumour | Hypopituitarism, DI, CSF rhinorrhoea, bleeding [5] |
| High-dose corticosteroids | GCA | Osteoporosis, DM, infection, peptic ulcer, AVN, adrenal suppression |
| HCQ | SLE (prevention of retinal toxicity) | Bull's eye maculopathy if dose not monitored |
Treatment of chronic complications — principles: (1) Prevention — good glycaemic control. (2) Incipient (subclinical) stage — reversible (e.g. microalbuminuria): improve glycaemic control, treat other risk factors (BP, smoking), pharmacological intervention: ACEI/ARB, SGLT2 inhibitors/GLP-1 receptor agonists, finerenone. (3) Overt complications — albuminuria, moderately severe retinopathy, clinical neuropathy: progression slowed by ↑glycaemic control, risk factor management, specific treatments (e.g. laser therapy, foot care), symptomatic treatments (dialysis, pain relief). Prevention of drastic consequences — laser therapy; foot care. [26]
This GC lecture slide provides the overarching framework: prevention → early detection → slow progression → treat complications → rehabilitate.
High Yield Summary — Complications of Chronic Visual Loss
- DR complications are VEGF-driven: vitreous haemorrhage (PDR), tractional RD (PDR), rubeotic glaucoma (VEGF acts on iris when whole retina is ischaemic), DMO (any stage). Anti-VEGF targets the root cause.
- Neovascular glaucoma is a feared complication of PDR — new vessels grow into the drainage angle → fibrovascular membrane blocks outflow → ↑↑IOP. Requires urgent PRP + anti-VEGF + IOP-lowering.
- Absence of DR in a DM patient with renal impairment is a red flag for non-diabetic nephropathy [24].
- Graves' sight-threatening complications: compressive optic neuropathy ( < 5%), exposure keratopathy, secondary OAG [6].
- PRP complications: ↓night vision, ↓VF, ↓VA — these are the trade-off for saving central vision from PDR [18].
- Ethambutol optic neuropathy is generally reversible if caught early but can be permanent if continued. Dose-adjust in renal impairment [20][25].
- Falls are a major systemic complication of all causes of chronic visual loss in the elderly — cataract surgery reduces fall risk by ~34%.
- Charles Bonnet syndrome: formed visual hallucinations in patients with severe visual loss — patient retains insight. Reassure, not a psychiatric disorder.
- Intravitreal steroid complications: ↑IOP in ~30%, cataract acceleration — monitor closely.
- DM eye complications span the entire eye: lacrimal (↓tears), EOM (CN palsies), lens (cataract, refractive fluctuation), angle (rubeotic glaucoma), retina (DR/DMO) [22].
Active Recall - Complications of Chronic Visual Loss
References
[1] Senior notes: Ryan Ho Opthalmology, pp. 66–67, 73, 129 (Retinal vascular complications; hypertensive retinopathy complications; Graves' ophthalmopathy complications) [4] Senior notes: Ryan Ho Endocrine, pp. 94–96 (Chronic diabetic complications classification; DR pathophysiology and complications) [5] Senior notes: Block A - I keep on bumping into people on my side: pituitary tumours; hypopituitarism.pdf, p. 11 (Surgical complications of pituitary tumour treatment) [6] Senior notes: Ryan Ho Endocrine, p. 27; Ryan Ho Opthalmology, p. 129 (Sight-threatening complications of Graves' ophthalmopathy) [8] Senior notes: Gen Clerk Anaes + Microbiology Summary, p. 41 (Ethambutol — avoid in poor renal function) [18] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai), pp. 1518–1520 (PRP complications; vitrectomy indications) [20] Senior notes: Ryan Ho Respiratory, p. 89 (Ethambutol — generally reversible; contraindications including renal insufficiency) [22] Senior notes: Block A - Deterioration of eyesight in a diabetic patient: diabetic complications.pdf, pp. 1, 10 (Five important DM ocular complications; principles of chronic complication treatment) [23] Senior notes: Adrian Lui Pediatrics Notes, p. 303; Ryan Ho Endocrine, p. 94 (Chronic DM complications classification; annual screening) [24] Senior notes: Block A - Nephrology Interactive Tutorial.pdf, p. 4 (Red flags for non-diabetic nephropathy — absence of retinopathy) [25] Senior notes: Block A - Drugs and the Kidney.pdf, p. 1 (Ethambutol optic neuritis in renal impairment) [26] Lecture slides: GC 042. Deterioration of eyesight in a diabetic patient diabetic complications [Update 2025].pdf, pp. 14–15 (Treatment of chronic complications — principles)
High Yield Summary
Chronic visual loss = progressive, insidious decline in VA and/or VF.
Three anatomical categories (from GC lecture framework):
- Cloudy media (↓red reflex): cataract (most common globally), corneal opacity, vitreous opacity.
- Retinal disease (normal red reflex): DR (commonest cause of visual loss in DM), ARMD (commonest cause of irreversible central vision loss in elderly), retinitis pigmentosa.
- Optic nerve (normal red reflex, RAPD+): glaucoma (leading cause of irreversible blindness worldwide), compressive optic neuropathy (pituitary tumour → bitemporal hemianopia), toxic (ethambutol, methanol).
Key HK-relevant points:
- NTG is more common than high-pressure POAG in Chinese populations.
- PACG is more common in East Asians (shallow anterior chamber, hyperopic eyes).
- Nuclear sclerotic cataract causes myopic shift (AOS scenario: increasing myopia in an elderly patient).
- DR screening: annual dilated eye exam from T2DM diagnosis, T1DM after 5 years.
- DMO is the commonest cause of vision loss in DM patients.
- Ethambutol → optic neuritis; monitor VA and colour vision.
- RAPD is NOT caused by cataract (classic exam pitfall).
- Pinhole improves VA in refractive error/media opacity; does NOT improve VA in retinal/optic nerve disease.
High Yield Summary — Differential Diagnosis of Chronic Visual Loss
- Use the "front-to-back" anatomical framework: Media (↓red reflex) → Retina (fundoscopy abnormal) → Optic nerve (RAPD, disc pallor/cupping) → Visual pathway (homonymous VF defects).
- The "Big Four" (GC lecture) = Cataract, Glaucoma, DR/DMO, ARMD [2].
- Bedside triage: Red reflex (media vs not), pinhole (refractive vs neural), RAPD (optic nerve), VF pattern (localises lesion).
- Must-not-miss: Pituitary tumour (reversible with surgery), GCA (urgent steroids prevent bilateral blindness), neovascular glaucoma (urgent PRP), methanol (fomepizole + dialysis).
- HK-specific: NTG predominates over high-pressure POAG; PACG more common in Chinese; high myopia → myopic macular degeneration; DM prevalence high → DR screening critical.
- Cataract does NOT cause RAPD — this is the single most tested discriminator.
High Yield Summary — Diagnostics for Chronic Visual Loss
- Bedside algorithm = front to back: VA → pinhole → red reflex → RAPD → fundoscopy → VF. This sequence alone localises pathology in most cases.
- Key investigations per condition: Cataract = slit-lamp; Glaucoma = IOP + gonioscopy + OCT RNFL + HVF; DR = dilated fundoscopy + OCT macula ± FFA; ARMD = OCT ± FFA/ICGA; Compressive ON = MRI brain; GCA = ESR/CRP + temporal artery biopsy.
- 4-2-1 rule defines severe NPDR (> 50% progress to PDR): 4 quadrants haemorrhages, 2 quadrants venous beading, 1 quadrant IRMA. [14]
- ISNT rule: Inferior ≥ Superior ≥ Nasal ≥ Temporal rim thickness in normal disc. Violation suggests glaucoma. [13]
- IOP alone does not diagnose or exclude glaucoma. Thin CCT underestimates IOP (pachymetry important for NTG workup).
- OCT is the most important ancillary test — confirms DMO, ARMD subretinal fluid, glaucomatous RNFL thinning, macular hole, epiretinal membrane.
- MRI is preferred over CT for pituitary and orbital lesions (better soft tissue contrast) [5][17]; CT is adequate for Graves' if MRI unavailable.
High Yield Summary — Management of Chronic Visual Loss
- Phacoemulsification is the modern gold standard for cataract surgery [3]. Most common complication long-term = posterior capsule opacification (treated by YAG laser capsulotomy).
- Glaucoma: Only proven treatment = IOP lowering. PGA drops 1st-line. β-blockers C/I in asthma/COPD/heart block. SLT is an alternative 1st-line. Trabeculectomy for refractory cases. Lens extraction increasingly used for chronic PACG.
- DR management is stage-dependent: Mild/moderate NPDR = systemic control + monitor. Severe NPDR/PDR = PRP. DMO = intravitreal anti-VEGF (1st-line). PRP complications: ↓night vision, ↓VF, pain. [18]
- Dry ARMD: no cure — AREDS2 supplements + RF modification. Wet ARMD: intravitreal anti-VEGF 1st-line [1]. PDT for PCV (common in Asians).
- GCA: DO NOT DELAY steroids. Prednisolone 60 mg/day (or IV methylprednisolone if visual symptoms). [15] Tocilizumab for steroid-sparing.
- Pituitary tumour with visual field deficits → transphenoidal surgery. Exception: prolactinoma → medical therapy with dopamine agonist first. [5]
- Anti-VEGF agents do NOT require stopping antiplatelets/anticoagulants. [18]
- HCQ: annual retinal screening from year 5; keep dose < 5 mg/kg/day. [21]
High Yield Summary — Complications of Chronic Visual Loss
- DR complications are VEGF-driven: vitreous haemorrhage (PDR), tractional RD (PDR), rubeotic glaucoma (VEGF acts on iris when whole retina is ischaemic), DMO (any stage). Anti-VEGF targets the root cause.
- Neovascular glaucoma is a feared complication of PDR — new vessels grow into the drainage angle → fibrovascular membrane blocks outflow → ↑↑IOP. Requires urgent PRP + anti-VEGF + IOP-lowering.
- Absence of DR in a DM patient with renal impairment is a red flag for non-diabetic nephropathy [24].
- Graves' sight-threatening complications: compressive optic neuropathy ( < 5%), exposure keratopathy, secondary OAG [6].
- PRP complications: ↓night vision, ↓VF, ↓VA — these are the trade-off for saving central vision from PDR [18].
- Ethambutol optic neuropathy is generally reversible if caught early but can be permanent if continued. Dose-adjust in renal impairment [20][25].
- Falls are a major systemic complication of all causes of chronic visual loss in the elderly — cataract surgery reduces fall risk by ~34%.
- Charles Bonnet syndrome: formed visual hallucinations in patients with severe visual loss — patient retains insight. Reassure, not a psychiatric disorder.
- Intravitreal steroid complications: ↑IOP in ~30%, cataract acceleration — monitor closely.
- DM eye complications span the entire eye: lacrimal (↓tears), EOM (CN palsies), lens (cataract, refractive fluctuation), angle (rubeotic glaucoma), retina (DR/DMO) [22].